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Abstract 
In eukaryotes, DNA is packaged into chromatin, which consists of the DNA 
wrapped around an octameric core of histone proteins (H2A, H2B, H3, and H4) 
which collectively comprise the nucleosome.  Gene activation and silencing 
determined by the access of transcriptional machinery to DNA can be dictated in 
part by dynamic post-translational modifications (PTMs) on histone proteins. 
These PTMs can be added, removed, and interpreted by chromatin effector 
complexes that interact with chromatin. In yeast, the highly conserved histone 
acetyltransferase (HAT) Gcn5 associates with Ada2 and Ada3 to form the 
catalytic module of the ADA and SAGA transcriptional coactivator complexes. 
Gcn5 also contains an acetyl-lysine binding bromodomain that has been 
implicated in regulating nucleosomal acetylation in vitro, as well as at gene 
promoters in cells. However, the contribution of the Gcn5 bromodomain in 
regulating site specificity of HAT activity remains unclear.  
Here, we used a combined acid-urea gel and quantitative mass 
spectrometry approach to compare the HAT activity of wild-type and Gcn5 
bromodomain-mutant ADA subcomplexes (Gcn5-Ada2-Ada3). Wild-type ADA 
subcomplex acetylated H3 lysines with the following specificity; H3K14 > H3K23 
> H3K9 ≈ H3K18 > H3K27 > H3K36. However, when the Gcn5 bromodomain 
was defective in acetyl-lysine binding, the ADA subcomplex demonstrated 
altered site-specific acetylation on free and nucleosomal H3, with H3K18ac being 
the most severely diminished. H3K18ac was also severely diminished on 
H3K14R, but not H3K23R, substrates in wild-type HAT reactions, further 
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suggesting that Gcn5-catalyzed acetylation of H3K14 and bromodomain binding 
to H3K14ac are important steps preceding H3K18ac. Consistent with our in vitro 
results, when the Gcn5 bromodomain was impaired in vivo we observed a global 
decrease in H3K18 acetylation. 
In sum, this work details a previously uncharacterized cross-talk between 
the Gcn5 bromodomain "reader" function and enzymatic HAT activity that might 
ultimately affect gene expression. Through our development of in vitro assays 
that contain selectively modified histones and intact epigenetic complexes and 
modules, we can gain biologically relevant insight into the activity and chromatin 
interactions of effector protein complexes. Future studies of how mutations in 
bromodomains or other histone post-translational modification readers can affect 
chromatin-templated enzymatic activities will yield unprecedented insight into a 
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Chapter 1: General Introduction 
 
1.1 Epigenetics 
Epigenetics is classically defined as heritable changes in gene expression and 
phenotype that are independent of DNA nucleotide sequence (1-3). There are 
approximately 250 different types of cells in the human body that can vary 
phenotypically in both appearance and function, yet each of these cell sub-types arises 
from the same DNA template (4). Alterations in phenotype from the same DNA 
sequence is established through elaborate control of gene expression, that is, whether a 
gene is actively expressed or whether it is transcriptionally silenced (1-3, 5, 6). 
Epigenetic mechanisms that determine gene expression without altering the DNA 
sequence of a gene include DNA methylation, histone modifications, and RNA 
interference (1-3, 5, 6). These mechanisms of epigenetic regulation are involved in 
fundamental biological processes of eukaryotes such as cell differentiation, stem cell 
renewal, cell aging, and when they are misregulated, disease states arise (7-9).  
 
1.2 The Nucleosome and Chromatin 
Gene expression is dictated in part by the accessibility of underlying DNA to 
transcriptional machinery (5). In eukaryotes, DNA is packaged into chromatin, which 
consists of 146 base pairs of DNA wrapped around an octameric core of histone 	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 proteins (10-12). This octamer contains two copies each of histones H2A, H2B, H3, 
and H4 where histones H3 and H4 interact as a tetramer and histones H2A and H2B 
fold into the octamer as two dimers (Figure 1A) (10, 11).  This arrangement of DNA and 
histone proteins collectively comprises the nucleosome, which is the fundamental 
repeating unit of chromatin (Figure 1A) (5, 10, 11). Nucleosome linkage is facilitated by 
histone H1 that is outside of the core octamer and acts to stabilize nucleosome 
arrangement into chromatin fibers (13). Histones themselves are relatively small 
proteins (~ 11 – 18 kDa) that contain a globular core region in addition to flexible N-
terminal extension or “tail” that extends outward from the nucleosome, through the 
gyres of the nucleosomal DNA (10, 11). Histones contain many arginine and lysine 
residues, especially within the tail region, which bestows an overall basic charge which 
is thought to play a significant role in the regulation of nucleosomal and chromatin 
structure (10, 11). 
Chromatin can exist in higher-ordered structures known as euchromatin and 
heterochromatin (Figure 1B) (12, 14, 15). Euchromatin is considered a transcriptionally 
active state where DNA is less densely packed with histone proteins, thereby allowing 
access of transcription factors to underlying genes (13, 14, 16-18). In contrast, 
heterochromatin is a tightly compact state to which transcriptional machinery is 
restricted access to DNA and thereby gene transcription is inaccessible (5, 16). The 
maintenance of chromatin organization can depend on the biological state of the cell, 
and the region and the function of the chromosomal locus, and is dictated by several 
factors such as histone chaperones, chromatin remodelers, and histone effector protein 
complexes (19-23).  
	   4	  
1.3 Histone Post-Translational Modifications 
1.3A Histone modifying enzymes 
Euchromatin and heterochromatin states can be distinguished in part by various 
post-translational modifications (PTMs) present on histone proteins (5, 23-25). These 
modifications include but are not limited to acetylation, methylation, phosphorylation, 
and ubiquitylation (Figure 2A) (17, 25-27). PTMs are found to a high degree on the 
flexible, N-histone tails, and are also found to a lesser extent within the globular region 
of histone proteins (5, 17, 23-28). These PTMs are extremely dynamic in nature, which 
is due to histone modifying enzymes that can add, or remove PTMs (Figure 2B) (17, 
24, 25, 28). Histone modifying enzymes that add PTMs to histone proteins, such as 
histone acetyl-transferases (HATs) which enzymatically add acetyl moieties to lysine 
residues, and histone methyl-transferases (HMTs), which catalyze the addition of 
methyl groups to lysine or arginine residues, are termed “writers” (29-31). Those 
enzymes that remove histone PTMs, or “erasers”, include histone deacetylases 
(HDACs) that remove lysine acetylation and histone demethylases (DMTs), which 
remove methyl groups from lysines and arginines (29-31). 
Additionally, there are non-enzymatic domains that can bind to or interact with 
modified residues known as “readers”. Readers can recognize the PTM and 
surrounding residues in the histone sequence, which allows these reader-containing 
proteins and complexes to distinguish between similar PTMs. These reader domains 
can vary in both their recognition motifs and structure. For example, the reader known 
as a bromodomain, is an acetyl-lysine binding motif that consist of a four alpha-helical 
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  structure (32, 33). In contrast, the reader domain known as a PHD (plant 
homeodomain) finger is capable of binding to di- and tri-methylation states on both 
H3K4 and H3K9 and are structurally characterized by a two-stranded antiparallel β-
sheet and three loops stabilized by Zn2+ molecules (34-39). 
1.3B The histone code hypothesis 
PTMs, either individually or in combination, can act to determine chromatin structure 
by serving as a docking site for chromatin interacting proteins that bind to modified 
histones through protein-protein interactions via reader domains (Figure 2B) (25, 27, 
28, 33, 43). The existence of an epigenetic or histone “code” has been hypothesized 
and states that a distinct PTM or set of PTMs can specifically recruit or occlude effector 
protein complexes to chromatin, which can  thereby elicit a downstream biological effect 
within the cell (25, 27, 28, 33, 43). This hypothesis is supported by the association of 
specific PTMs with cellular processes. For example, during gene transcription, histone 
H3 lysine 4 trimethylation (H3K4me3) is associated with transcription initiation as it is 
enriched at the gene’s 5’-end at the transcription start site, while histone H3 lysine 36 
trimethylation (H3K36me3) is associated with transcriptional elongation and enriched 
within the gene body (34, 44-46). 
 This hypothesis is further supported by the presence of distinct combinations of 
readers, writers, and erasers present within various effector complexes that could allow 
for interpretation of a histone code (16, 25, 28, 36, 43). For example, bromodomains are 
often found within the same protein or protein complex as HATs, but are also found in a 
diverse range of proteins including chromatin remodelers, helicases, and transcriptional 
coactivators (41, 42). Because chromatin effector complexes are often found with many 
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subunits that contain multiple effector and reader functions, such as the 19-subunit 
SAGA complex, combinatorial PTMs may act to specify localization and activity of these 
complexes (33, 36, 43, 47). 
1.3C Lysine acetylation 
PTMs can also determine chromatin structure by altering the affinity of DNA to 
histone proteins(18). For example, when a positively charged histone lysine residue is 
acetylated that charge is neutralized and in turn decreases the affinity of the histone 
protein to the negatively charged DNA backbone. Therefore, regions of chromatin that 
contain a high degree of lysine acetylation are typically transcriptionally active (Figure 
2A) (16, 18, 48-51). Genes found within areas of the genome that contain a low degree 
or hypoacetylation are usually silenced (Figure 2A) (16, 26, 51). The discovery of 
histone lysine acetylation dynamics and the writers, readers, and erasers responsible 
for this modification have led to groundbreaking studies that have shaped our 
understanding of epigenetic regulation and gene expression. 
Lysine acetylation was hypothesized to play a role in gene expression in the 1960’s 
when it was observed that acetate was incorporated and deposited on histone proteins 
from isolated nuclei (52-54). Furthermore, this same group suggested the reversibility of 
lysine acetylation and linked it to regulation of RNA synthesis (52, 53). Subsequent 
studies using acetyl-lysine specific antibodies on polytene chromosomes indicated that 
specific acetylation sites occurred at various regions within the chromosome suggesting 
histone acetylation may act to impact chromatin structure and function (53, 55, 56). This 
relationship was further emphasized by mutations to histone lysine residues in yeast 
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and their impact on transcription. However, it was not until the discovery of the first 
nuclear HAT, Gcn5, and its acetylation of histone H3 that a clear link between histone 
acetylation and its transcriptional activation of genes was established (53, 57). With 
advances in proteomics, lysine acetylation has been implicated on a global level within 
the cell, as there have been at least 1,750 proteins and 3,600 acetylation sites identified 
(53, 58). In regard to gene expression, lysine acetylation is carefully regulated through 
the interplay of HATs and HDACs and has been known to play a role in several 
biological processes in addition to transcriptional activation such as DNA repair, histone 
deposition, and chromosome condensation (18, 29, 48, 50, 51). 
 
1.4 The Histone Acetyltransferase Gcn5 
1.4A Gcn5 is a reader and writer of lysine acetylation 
Gcn5 (general control non-derepressible) was the first nuclear HAT discovered, 
purified from nuclear extracts of the eukaryotic protozoan, Tetrahymena thermophila, 
and linked to histone acetylation and gene transcription in yeast  (57). Gcn5 is highly 
conserved from yeast through humans and has the ability to write lysine acetylation via 
its catalytic HAT domain and also bind to acetyl-lysine residues through its adjacent 
bromodomain (Figure 3A) (32, 40, 73, 74). While Gcn5 has been primarily associated 
with transcriptional activation through its acetylation of histone proteins, it also  	  	  
acetylates non-histone substrates such as CDK5 and PGC-1α, which implicate Gcn5 in 
in cell cycle progression and metabolic pathways (Figure 3B) (75-77). Since the 
hallmark discovery of Gcn5 linking histone acetylation to gene transcription, many 
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  elegant studies deciphering Gcn5 structure, enzymatic activity, inhibition, and 
transcriptional regulation have been published which are described in detail below 
(Figure 4) (57, 78-84). 	  
1.4B Gcn5 is found in several multi-subunit protein complexes 
Gcn5 has been found to exist in several multisubunit protein complexes, such as 
the SAGA complex, that contribute to transcriptional activation (Figures 5A, 5B) (79). 
SAGA plays a pivotal role in transcriptional as it has been found to act on the entire 
transcribed genome with functions that include initiation, elongation, RNA pol II 
recruitment, TBP interaction, histone acetylation and ubiquitination (47, 85). 
Additionally, SAGA has been shown to act in maintaining DNA integrity and is involved 
in mRNA export (47). While the 1.8 MDa SAGA complex, which contains about 19 
protein subunits, remains highly conserved from yeast through humans, Gcn5 is found 
in several other effector protein complexes that diverge throughout evolution (Figure 
5B) (47). In addition to SAGA, several additional Gcn5-containg complexes exist 
(Figures 5A, 5B) (47). Yeast contain a related SAGA complex, known as SLIK (or 
SALSA) which contains a truncated version of the Spt7 protein and has the additional 
protein Rtg2 linking it to the mitochondrial retrograde response pathway (47, 86).  The 
function of the yeast-specific ADA complex, which is a smaller Gcn5-containing complex 
(0.8 MDa), has yet to be determined and its Ahc1 and Ahc2 components do not appear 
to be conserved in higher eukaryotes (87, 88). The ~14 subunit Gcn5-containing ATAC 
complex is not found in yeast but is found exclusively in multicellular organisms (47, 64, 
89). In mammals, the emergence of a related but distinct HAT, known as PCAF evolved 
and is highly homologous to Gcn5 with 75% identity to Gcn5 at the protein level
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 (47, 90-92). 	  Both Gcn5 and PCAF interact with the Ada2 and Ada3 proteins to form a 
trimeric subcomplex (47, 79, 93-97). Therefore, humans contain two versions of SAGA 
and two versions of ATAC with either Gcn5 or PCAF acting as the HAT (47, 89, 98). 
Interestingly, the in vitro HAT activities showed that SAGA primarily acetylates histone 
H3 while ATAC had specificity toward histone H4 in nucleosomes (47, 89, 98, 99).  
1.4C Functions of Gcn5 in development 
Gcn5 plays a very crucial role in mammalian development requiring proper Gcn5 
expression levels for normal development (8, 100-102). Deletion of Gcn5 is embryonic 
lethal in mice with extreme growth defects and cell death occurring at 8.5 days. 
Interestingly, mice with a catalytically inactive Gcn5 HAT domain survive longer than 
those with a null Gcn5 allele suggesting Gcn5 plays a role in early development that 
may be independent of its enzymatic histone acetyltransferase activity (64, 100).  
Furthermore, deletion of both Gcn5 and PCAF resulted in more severe defects, but 
deletion of PCAF alone results in no change in developmental phenotype (64, 100). 
This suggests that Gcn5 and PCAF have may have distinct but overlapping functions 
within the cell. Interestingly, PCAF has been reported to contain E3 ubiquitin ligase 
activity that affects downstream degradation of p53 levels (103, 104). It is currently 
unknown whether Gcn5 is also able to carry out E3 ubiquitin ligase activity.  
When Gcn5 was deleted in embryonic stem cells, they were still able to 
differentiate undergo normal growth conditions (64, 102). However, as differentiation 
progressed in Gcn5 null cells it resulted in aberrant gene expression of pluripotent stem 
cell specific transcription factors such as Nodal and Oct4, which were found to be 
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  decreased upon deletion of Gcn5 (64, 102). Therefore the ability of stem cells to self-
renew depends on the presence of Gcn5.  
	  1.4D Implications of Gcn5 in disease	  
Gcn5 has been linked to several disease states including neurological disease, 
cancer, respiratory disease, and metabolic conditions (9, 60-62, 64, 105). The genetic 
and incurable disease known as spinocerebellar ataxia type 7 is caused by a polyQ 
expansion in the SAGA subunit, Atxn7 (60, 62, 106, 107). This disease was found to be 
accelerated upon Gcn5 deletion in mice and when the expanded polyQ-Atxn7 was 
incorporated in SAGA, nucleosome acetylation was shown to impaired implicating a role 
for Gcn5 in this disorder (60, 108). Additionally, because Gcn5 regulates cell cycle 
progression and growth it has been associated with cancer and oncogenic 
transformation. Gcn5 has been shown to interact with the oncoprotein, Myc, where it is 
not only recruited to acetylate Myc-targeted genes, but Myc itself is stabilized upon 
acetylation by Gcn5 (109, 110). It has recently been shown that Gcn5 is upregulated 
and overexpressed in non-small cell lung cancer tumors in which it contributes to cell 
growth by increasing the expression of cyclins D1 and E1 and the protein E2F1 (64, 75, 
105). Additionally, Gcn5 has been shown to play a role in respiratory diseases such as 
asthma and COPD and could be a potential target in metabolism disorders as it is tightly 
tied to regulation of the transcription factor, PGC-1α, which regulates gluconeogenesis 
(65, 76, 77). The implication of Gcn5 in these disorders merits further understanding of 
how its HAT activity and substrate specificity might be impaired or altered within these 
disease states. In addition to identifying Gcn5 acetylation sites and substrate targets, 
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understanding how these substrates might be acetylated in a site specific or processive 
order could lend insight into targeting Gcn5 catalytic activity in a therapeutic manner.  
 
1.5 Drugging the Epigenome 
1.5A Therapeutic rationale 
Epigenetics has emerged as an attractive field for therapeutic intervention. 
Because epigenetics plays such a fundamental role in many disease states such as 
cancer, metabolic disease, cardiovascular, and neurological diseases the impact of 
targeting proteins involved in epigenetic regulation holds great promise (7, 9, 39, 59-64). 
Moreover, it is the potentially reversible nature of epigenetic states that makes this field 
so promising to pharmacology (9). Small molecule inhibitors designed to block certain 
histone interacting proteins have already proved effective against certain cancers and 
neurological diseases (9, 65). 
1.5B HDAC inhibitors 
The HDAC family of epigenetic proteins is structurally diverse and they are 
divided into four classes, which begs the need for specific inhibitors when targeting 
these enzymes. HDAC inhibition has been successful in treating cancer and 
neurological disease. Vorinostat (also known as SAHA) targets Class I and II HDACs 
and has been approved in 2006 for the treatment of cutaneous T-cell lymphoma (65-
67). Additionally, valproic acid, a general HDAC inhibitor, is an anticonvulsant that is 
also used to stabilize mood (65).  HDAC inhibition is currently being studied for 
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diseases like Alzheimer’s disease and holds promise for further disease intervention 
(65). 
1.5C Bromodomains as drug targets 
There are 61 known bromodomains in humans that are found in 46 
bromodomain-containing proteins (65, 68, 69). These bromodomain-containing proteins 
are involved in oncogenic rearrangements, the transcriptional regulation of viral 
genomes, and mediation of the inflammatory transcription factor NF-kB (65, 68-70). The 
small molecule bromodomain inhibitors, JQ1 and I-BET, target the bromodomain of the 
BET protein, Brd4, show extreme promise for therapeutic potential  (65, 70-72). JQ1 
has been used to treat midline carcinoma while I-BET has been shown effective against 
inflammation associated with septic shock (65, 71). Both JQ1 and I-BET are currently 
under active investigation in areas such as cardiovascular disease, cancer, and male 
contraception (65, 71).  
The success of BET bromodomain inhibition sets the stage for the development 
of small molecules against “reader” domains that act by disrupting protein-protein 
interactions instead of ablating enzymatic activity. Because bromodomains and 
bromodomain-containing proteins are often found adjacent to HATs within the same 
protein or within the same complex as HATs, determining if the bromodomain acts to 
affect catalytic activity could further establish this reader as a druggable target. 
Therefore, understanding if reader domains, such as the bromodomain, act to regulate 
catalytic activity of writers could provide unprecedented insight into pharmacological 
targeting of the epigenome. 
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Chapter 2: Characterization of the Gcn5 
subcomplex HAT activity on histone H3 
 
This research was originally published in Molecular and Cellular 
Proteomics. Anne M. Cieniewicz, Linley Moreland, Alison E. 
Ringel, Samuel G. Mackintosh, Ana Raman, Tonya M. Gilbert, 
Cynthia Wolberger, Alan J. Tackett, and Sean D. Taverna. The 
Bromodomain of Gcn5 Regulates Site Specificity of Lysine 
Acetylation on Histone H3. Molecular and Cellular Proteomics. 
2014; 13: 2896-2910. © The American Society for Biochemistry 




2.1 Introduction  
Gcn5 has been shown to acetylate multiple histone lysine residues in vitro, with 
its primary target being lysine 14 of histone H3 (49, 57, 112-114). However, histone 
H3 lysines K9, K18, K23, K27, and K36 have also been reported to be acetylated by 
Gcn5 in addition to lysine residues found on histone H4 and H2B (39, 61, 101, 129, 
130). When regarding substrate specificity of Gcn5, it must be taken into consideration 
that in vivo Gcn5 is most always found in a complex with other protein subunits and 
does not exist as a monomer in the cell (79, 86, 88, 93, 115).  In vitro, monomeric Gcn5 
is unable to acetylate nucleosomal substrates, but Gcn5 nucleosomal acetylation is 
achieved when Gcn5 is in the presence of its binding partners Ada2 and Ada3 (95, 96, 
116-118). The minimal form of Gcn5 reported in vivo is the trimeric Gcn5-Ada2-
Ada3 subcomplex also referred to as the HAT A2 complex, in which the Gcn5 trimeric 
subcomplex is incorporated into even larger complexes such as SAGA and ADA (68, 
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76, 78, 83, 131). Gcn5 interacts with Ada2 through an Ada2-binding domain, and Ada2 
in turn binds to Ada3 (95, 96, 116-118). While Ada2 and Ada3 are nonenzymatic, 
they have been shown to affect Gcn5 substrate specificity and also its ability to engage 
higher-ordered substrates, such as the nucleosome, through DNA and histone binding 
domains (Figure 6A)  (95, 96, 116-118). Ada2 contains SANT, SWIRM, and Zinc-finger 
domains and it has been shown to potentiate Gcn5 catalytic activity on histone H3 (116, 
118). Ada3 was found to expand Gcn5 lysine specificity and is necessary for Gcn5 
nucleosome acetylation (96, 118). Therefore, when studying Gcn5 in vitro HAT activity, 
working with Gcn5 in the context of its binding partners, Ada2 and Ada3, is critical to 
determine biologically accurate substrate specificity.  
Utilizing quantitative mass spectrometry it has been reported that Gcn5 
acetylates histone H3 lysines in the order of K14 > K23 > K9 = K18 > K27 > K36 
(113). However, this study was performed using monomeric Gcn5. Testing how Ada2 
and Ada3 might affect enzymatic Gcn5 HAT activity would provide a more biologically 
relevant interpretation of histone acetylation. In addition to histone H3, Gcn5 has been 
reported to target lysines on histone H4 and H2B, but how this acetylation occurs in the 
context of its binding partners as opposed to monomeric Gcn5 is currently unknown (49, 
114). Therefore, analyzing the Gcn5 catalytic site specific acetylation on histone 
substrates will provide valuable insight as to how Gcn5 functions in the context of 
biologically relevant complexes.  
Here, we aim to better understand Gcn5 HAT activity on histone proteins in the 
context of its binding partners Ada2 and Ada3. An in vitro assay with recombinant 
Gcn5 subcomplex and recombinant histones was developed to assess enzymatic 
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 activity. Utilizing acid-urea gels, we were able to determine how many lysines were 
acetylated on each histone and allowed for the comparison of overall acetylation pattern 
on different substrates such as free histones vs. histone octamers. Finally, semi-
quantitative mass spectrometry identified which lysines were acetylated and when used 
in combination with acid-urea gels, which separated distinct acetylated 
isoforms, Gcn5 subcomplex site specificity on histone H3 was uncovered where we 




2.2A Cloning, recombinant expression, and purification of full-length 
Gcn5 (Gcn5/Ada2/Ada3) subcomplex  
The pST44-yAda3t2HISx3-yAda2x3-yGcn5x5 polycistronic vector containing yeast 
GCN5, ADA2, and ADA3 obtained courtesy of Dr. Song Tan (Penn State, PA), originally 
encoded a truncated form of Ada3 (missing the N-terminal residues 1-184) (33).  Full-
length Ada3 was generated using nested primers to extend the truncated ADA3 
fragment, which was cloned into the pST44 vector (Figure S1). The expression of full-
length Gcn5/Ada2/Ada3 subcomplex and subsequent purification with Talon metal 
affinity resin (Clontech) and a FPLC SourceQ column (GE Healthcare) was performed 
as previously described  (117).  
2.2B In vitro histone acetyltransferase assays  
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 HAT assays were performed with full-length recombinant Gcn5/Ada2/Ada3 
subcomplex using 1 µg of recombinantly expressed S. cerevisiae free histone H3 or 1ug 
histone H3 in the context of the histone octamer, and 30 µM acetyl CoA in HAT reaction 
buffer (20 mM Tris pH 7.5; 50 mM NaCl; 5% glycerol) in a total volume of 60 µl.  For 
HAT assays with variable enzyme concentrations, reactions were incubated for 30 mins 
at 30˚C, followed by flash freezing in liquid nitrogen to stop the reaction. Samples were 
then lyophilized. Acetyl CoA was omitted from the control reactions. HAT reactions 
analyzed by quantitative mass spectrometry were performed in triplicate using 150 nM 
of WT or Y413A ADA subcomplex and carried out at 30˚C for 30 mins. 
2.2C Acetic anhydride treatment of recombinant histone H3 for 
positive controls 
To obtain maximally acetylated histone H3 control, 200 µg recombinant S. 
cerevisiae histone H3 was subjected to in vitro acetylation as previously outlined  (119).  
Acetylated histone H3 was purified and desalted using HPLC purification, and fractions 
were combined, flash frozen, and lyophilized.  Concentrations were normalized using a 
Ponceau stained dot blot. 
2.2D Resolution of histone H3 with SDS PAGE and acid-urea gel 
electrophoresis 
All lyophilized samples were resuspended in Laemmli loading buffer.  Running 
chambers were washed with methanol to prevent keratin contamination. NuPAGE SDS 
PAGE 12% gels (Invitrogen) were used to resolve histone H3.  Acid-urea gels were 
assembled and run as previously described  (120). Gels were washed with nano-pure 
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water and stained with SimplyBlue Safe Stain (Invitrogen). Bands were individually 
excised using a clean scalpel, and frozen for subsequent mass spectrometric analysis. 
2.2E Western blot analysis of site-specific histone H3 lysine 
acetylation 
Histone H3 samples were resolved by SDS PAGE and were transferred to a 
PVDF membrane using a semi dry transfer system.  Samples resolved by acid-urea 
gels were transferred to a PVDF membrane as previously described (106).  Membranes 
were blocked overnight in 5% milk at 4˚C and washed in Tris Buffer Saline (TBS).  
Primary antibodies were diluted in 1% milk in TBS and 0.1% Tween (TBST) as follows 
for nucleosomes (Figure 6) and Supplementary Figure 2: anti-H3 (Abcam ab1791, 
1/50,000); anti-H4 (Abcam ab10158-25, 1/5,000); anti-H2B (Abcam ab1790-25, 
1/20,000); anti-H3K9ac (Abcam, 1/5000); anti-H3ac (Millipore, 1/5,000); anti-H3K14ac 
(ab52946, Abcam, 1/5000); anti-H3K18ac (Active Motif 39130, 1/10,000); anti-H3K23ac 
(Active Motif 39132, 1/20,000); anti-H3K27ac (Active Motif 39134, 1/10,000); anti-
H3K56ac (Upstate, 1/10,000).  The following antibodies were used for histone K to R 
mutants: anti-H3K14ac (ab46984, Abcam, 1/500); anti-H3K18ac (Millipore 07-354, 
1/7,500); anti-H3K23ac (Millipore 07-355, 1/5,000);. Each primary antibody was applied 
for 1 hour at room temperature followed by washing in TBST.  Goat anti-rabbit IgG-
horseradish peroxidase secondary antibody (Amersham Biosciences) was diluted to 
1/4000 in 1% milk and TBST and applied for 1 hour at room temperature and washed in 
TBST.  Blots were developed using Pierce ECL Western Blotting Substrate 
(ThermoScientific) and exposed using film. 
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2.2F Mass Spectrometry 
Gel bands excised from acid-urea gels were de-stained (serially washed with 50 
mM ammonium bicarbonate in 50% methanol), treated with 30% d6-acetic anhydride in 
100 mM ammonium bicarbonate to chemically acetylate lysines (121), and subjected to 
in-gel trypsin digestion (100 ng trypsin, 37°C 15 hr). Treatment with d6-acetic anhydride 
adds isotopically heavy acetyl groups (+45Da) to unmodified and monomethylated 
lysines, which serves to prevent trypsin digestion at lysine residues with a 
distinguishable synthetic modification. This heavy acetylation enhances the 
identification of histone peptides  (121, 122). Tryptic peptides were separated by 
reverse phase Jupiter Proteo resin (Phenomenex) on a 100 x 0.075 mm column using a 
nanoAcquity UPLC system (Waters).  Peptides were eluted using a 45 min gradient 
from 98:2 to 40:60 buffer A:B ratio.  [Buffer A = 0.1% formic acid, 0.05% acetonitrile; 
buffer B = 0.1% formic acid, 75% acetonitrile.]  Eluted peptides were ionized by 
electrospray (1.9 kV) followed by MS/MS analysis using collisioninduced dissociation on 
an LTQ Orbitrap Velos mass spectrometer (Thermo)  (123-125).  MS data were 
acquired using the FTMS analyzer in profile mode at a resolution of 60,000 over a range 
of 375 to 1500 m/z.  MS/MS data were acquired for the top 15 peaks from each MS 
scan using the ion trap analyzer in centroid mode and normal mass range with a 
normalized collision energy of 35.0. Mass spectrometric data was database searched 
with Mascot using heavy and light acetylation of lysines as variable modifications. The 
percentage of site-specific lysine acetylation was determined with spectral count 
comparisons of peptides with light or heavy acetylation at the given lysine [% light 
acetylation for a lysine in a given peptide = (light spectral counts / light + heavy spectral 
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counts) x 100]. The standard deviation was calculated from triplicate measurements of 
spectral counts. Spectral counting provided a robust, semi-quantitative approach for 
initial analysis of site-specific lysine acetylation.  
Tandem mass spectra were extracted by Thermo ExtractMSn version 1.0.0.8. 
Charge state deconvolution and deisotoping were not performed. All MS/MS samples 
were analyzed using Mascot (Matrix Science, London, UK; version 2.4.1). Mascot was 
set up to search the Con_uniprot_sprot_1 database (selected for S. cerevisiae, version 
4, 7034 entries) assuming the digestion enzyme trypsin. Mascot was searched with a 
fragment ion mass tolerance of 0.60 Da and a parent ion tolerance of 10.0 PPM. Acetyl 
of lysine and acetyl:2H(3) of lysine were specified in Mascot as variable modifications. 
Scaffold (version Scaffold_4.0.1, Proteome Software Inc., Portland, OR) was 
used to validate MS/MS based peptide and protein identifications. Peptide 
identifications were accepted if they could be established at greater than 50.0% 
probability by the Scaffold Local FDR algorithm. Protein identifications were accepted if 
they could be established at greater than 95.0% probability and contained at least 2 
identified peptides.  Protein probabilities were assigned by the Protein Prophet 
algorithm (126). Proteins that contained similar peptides and could not be differentiated 
based on MS/MS analysis alone were grouped to satisfy the principles of parsimony. 
Proteins sharing significant peptide evidence were grouped into clusters. The mass 
spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner 
repository  (127) with the dataset identifier PXD001167 (128-130). 
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 2.3 Results 
2.3A Development of an in vitro histone acetyltransferase assay 
The Gcn5 subcomplex was recombinantly expressed and purified using a 
polycistronic vector (Figure 6B). To test the activity of the Gcn5 subcomplex, it was 
incubated with acetyl-CoA, the cofactor of Gcn5, and recombinant histone H3 in either 
free form or in an octamer. An anti-histone H3 antibody was used to detect Gcn5 
subcomplex acetylation of histone H3, in which Gcn5 was found to acetylate both free 
and octameric histone H3 in vitro (Figures 7A, 7B). To further test Gcn5 HAT activity on 
histone H3 we used increasing concentrations of the Gcn5 subcomplex to better 
understand optimal concentrations of enzyme and substrate for detection using a 
western blot with anti-acetyl histone H3 antibody (Figure 7C).  
2.3B Gcn5 subcomplex acetylation of histone substrates 
Acid-urea gels are a valuable tool for studying protein acetylation as they 
separate proteins, including histones, by both size and charge (Figure 8) (120, 131). 
Because a positively charged lysine residue is neutralized upon the addition of an acetyl 
group, it is possible to resolve different histone acetylation states on acid-urea gels as 
the migration rate in the gel is decreased upon acetylation. When different charge states 
exist within a population of heterogeneously acetylated histones, resolution over an acid 
urea gel will result in the isoform mixture to separate into a “ladder” of distinct bands 
based on charge number. Each subsequent band present within the “ladder” represents 
the addition of an acetyl group. Therefore, the number of lysine residues acetylated or 
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  deacetylated by a particular HAT or HDAC can potentially be determined using an acid- 
urea gel. Additionally, overall acetylation pattern can be visualized by the formation, 
loss, and individual band enrichment of resolved histone band laddering. Therefore, 
acid-urea gels can provide valuable insight into HAT and HDAC enzymes when testing 
enzyme concentration gradients, time courses, and comparing various conditions. 
To determine how many lysine residues the Gcn5 subcomplex acetylates in vitro 
on each histone substrate, each free histone was independently reacted with the Gcn5 
subcomplex under steady-state conditions for 30 mins and resolved on an acid-urea 
gel. This endpoint assay provided us with the number of lysines acetylated on each 
histone substrate and served to determine which histone substrates are preferred by the 
Gcn5 subcomplex. From the acid-urea gel we determined the number of lysines the 
Gcn5 subcomplex was acetylating on each histone. Histone H3 was acetylated on 6 
lysine residues; histone H4 was tri-acetylated; histone H2A was mono-acetylated; 
histone H2B was penta-acetylated (Figure 9). Histone H3 acetylation was further 
analyzed by resolving HAT assays on an acid-urea gel that contained increasing 
concentrations of Gcn5 subcomplex with either free histone H3 or octamers. An 
antibody against histone H3 acetylation was used on the resolved histone H3 isoforms 
to further analyze Gcn5 subcomplex overall acetylation pattern. These results confirmed 
that the Gcn5 subcomplex resulted in a total of 7 histone H3 bands when resolved on 
an acid-urea gel, representing a total of 6 acetylation sites and an unacetylated histone 
H3 isoform (Figure 10A). Interestingly, the Gcn5 subcomplex histone H3 acetylation 
pattern differed between free histone H3 and octameric H3. The Gcn5 subcomplex 
appeared to 
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  acetylate octameric histone H3 to a greater degree at lower concentrations suggesting 
the histone octamer could be the preferred substrate over free histone H3 (Figure 10B). 
2.3C Gcn5 subcomplex acetylates histone H3 tail lysine residues with 
a site specific order in vitro  
When determining enzymatic activity of chromatin effector proteins, histone 
substrate specificity on multiple residues within the same protein, and elucidating the 
interplay between reader and writer functions, a sensitive and quantitative approach 
capable of detecting subtle changes in modifications on specific residues is required. 
Assays using radioisotopes of cofactors, such as acetyl CoA and SAM, have been used 
to evaluate bulk activity within a target polypeptide or mixture of proteins. However, 
radioisotope assays do not yield insight into site specificity (the modification of a specific 
residue relative to that of a proximal residue). In contrast, proteomic mass spectrometry 
approaches can yield detailed information about the specificity of a reaction regarding 
rates for specific residues (113, 132, 133). To accurately measure PTM abundance 
among different samples and conditions it is necessary to generate species that are 
chemically equivalent but isotopically distinct to ensure equivalent time of flight and yet 
exhibit a discernable mass difference. Utilizing isotopic chemical labeling we were able 
measure and compare acetylation and methylation on specific lysine residues within 
histone H3 via mass spectrometry.  
For measuring lysine acetylation we employed acetic anhydride treatment to 
chemically acetylate all unmodified lysine residues on a given protein. We further exploit 
this technique by using deutero-acetic anhydride to administer an isotopically heavier 
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label (121, 122, 134, 135). We tested this technique using histone H3 tail peptides in 
which we labeled all lysine residues with either acetic anhydride (light) or deutero-acetic 
anhydride (heavy) and mixing these peptides at different ratios, which were then 
measured using MALDI-TOF (Figure 11A) (121, 122, 134-138). We plotted our known 
(expected) ratio mixture of light:heavy against what we measured using MALDI-TOF 
and found our measured data points fit accurately with our expected values (Figure 
11B). 
We combined this quantitative mass spectrometry approach with acid-urea gel 
resolution to optimize a technique for determining in vitro lysine specific acetylation on 
histone proteins from a HAT assay using acetyl CoA as a cofactor (Figure 12 A – E). 
The HAT enzyme will target its given lysine residues depositing ‘light” acetyl marks. 
Because HAT enzymes can often target multiple lysine residues on a single protein, we 
first resolve these different acetylation states on an acid-urea gel. These bands are 
excised and subjected to deutero-acetic anhydride treatment where all unmodified 
lysine residues are now chemically labeled with “heavy” acetyl marks. Histone proteins 
are broken down into peptides using a tryptic digest that cleaves after unmodified 
lysines and arginines. Because each lysine residue is acetylated trypsin will cleave only 
after arginine resulting in an identical tryptic peptide fingerprint for all conditions. LC-
MS/MS analysis allows for the comparison of light:heavy signal on each individual lysine 
residue and we can thereby calculate the amount of acetylation catalyzed in a HAT 
reaction. 
Having established that the Gcn5 subcomplex acetylates six histone H3 lysine 
residues, we next hoped to identify which lysine residues were acetylated and if the 
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 acetylation of these lysine residues occurred in a site specific sequence or order. 
Utilizing our semi-quantitative mass spectrometry approach (Figure 12 A-E), we 
excised histone H3 acetylated isoforms from individual acid-urea gel bands and 
determined the percent acetylation on each histone H3 polypeptide. In agreement with 
previous studies, we observed acetylation on residues H3K9, H3K14, H3K18, H3K23, 
H3K27, and H3K36 (113). Moreover, as expected, no acetylation was detected on band 
0 (unacetylated) in the HAT reaction or the negative control reaction, further validating 
this approach as a way to cleanly separate and identify differentially acetylated histone 
species (Figure 13A). 
Because our dual acid-urea gel and mass spectrometry approach lends 
additional insight into site specificity of the Gcn5 subcomplex we posited that the 7 
histone H3 acetylated isoforms represented distinct reaction intermediates as histone 
H3 proceeded from an unmodified isoform (band 0), to a monoacetylated isoform (band 
1) and eventually to a hexa-acetylated isoform generated in our Gcn5 subcomplex HAT 
reaction. The observation that the acetylation pattern of Gcn5 subcomplex HAT activity 
occurred as an even distribution or “ladder” of acetylated H3 isoforms suggests 
progressive and unidirectional acetylation. Mass spectrometry analysis of acetylation 
abundance on individual lysine residues revealed K14 was acetylated at levels of 100% 
in band 1, the first reaction intermediate. K14 was acetylated to levels of 100% in the 
additional five acetylated histone H3 isoforms indicating K14 is the initial site of 
acetylation, which is in agreement with previous kinetic studies (113). In the di-
acetylated reaction intermediate (band 2) we observed that K23 was acetylated with an 
abundance of 100% in addition to 100% K14 acetylation, indicating that K23 acetylation 
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 occurs directly following K14 acetylation. In band 3, a mixture of H3 acetylated isoforms 
were present with a tri-acetylated intermediate that contained acetylation on K14, K23, 
and to a lesser degree K18 in addition to a second intermediate that contained 
acetylation on K14, K23, and to a lesser degree K9. In band 4, the tetra-acetylated 
state, K14, K23, K18, and K9 were all acetylated to levels close to 100% indicating that 
lysines K18 and K9 occur with similar site specificity, but are acetylated after K14 and 
K23 acetylation. Histone H3 was 100% acetylated on lysines K14, K23, K18, K9, and 
K27 while the final hexa-acetylated intermediate was entirely acetylated on residues 
K14, K23, K18, K9, K27, and K36 suggesting K27 and K36 are the fifth and sixth sites 
acetylated by the Gcn5 subcomplex (Figures 13A, 13B).  
To further validate and complement our mass spectrometry data, we used site-
specific antibodies against acetylated histone H3 lysine residues resolved on acid-urea 
gels (Figures 14A, 14B). These western blots indicated that acetylation occurred on the 
same six histone H3 tail lysine residues detected with mass spectrometry. However, 
because antibodies may exhibit a degree of cross reactivity and are not quantitative we 
were unable to conclude an order from western blot analysis alone, which further 
strengthened the utility of our dual acid-urea gel and mass spectrometry approach. 
 
2.4 Discussion 
We developed an in vitro HAT assay utilizing the biologically relevant Gcn5 
subcomplex to better understand the activity of the Gcn5 subcomplex on recombinant 
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 histone H3. HAT reactions were subjected to in-depth analysis acid-urea gel resolution, 
western blots using acetyl-lysine specific antibodies, and semi-quantitative mass 
spectrometry which allowed us to determine the number of lysine residues acetylated, 
the identity of these residues, and the site-specific acetylation of the Gcn5 subcomplex 
on histone H3. We observed that Gcn5 in the context of its binding partners, Ada2 and 
Ada3, acetylates histone H3 on six lysine residues in vitro with the following site 
specificity: K14 > K23 > K18 = K9 > K27 > K36 (Figure 15). 
Regarding the order of histone H3 lysine acetylation catalyzed by the Gcn5 
subcomplex, our data suggest that K14 was the preferred lysine residue as it was found 
to be acetylated at levels of 100% in all reaction intermediates including the mono-
acetylated isoform (band 1). Additionally, because subsequent downstream acetylation 
was found to occur sequentially in single increments it was reasoned that the Gcn5 
subcomplex acetylated lysines in a progressive and unidirectional manner. Had Gcn5 
acetylated its 6 lysine targets simultaneously, the evenly distributed “ladder” of seven 
bands would not be present and instead a single band occurring in the band 6 position 
would be observed. Therefore, a comparison of acetylation abundance on individual 
histone H3 lysines as histone H3 isoforms progress from a hypoacetylated (band 0) 
state to a hyperacetylated (band 6) state, reaction intermediates can be used to 
measure site specific acetylation on one lysine residue relative to another. 
Another group recently found that following the acetylation of H3K14, Gcn5 
acetylation lysines H3K9 and H3K23 occurred at similar rates, whereas our data clearly 
showed H3K23ac occurred before H3K9ac (113). In contrast, we observed that it was 
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 H3K9ac and H3K18ac that had similar site specificity when reacted with Gcn5. A 
possible reason for this difference may be due to the fact that our approach enabled 
greater resolution of histone H3 reaction intermediates due to the separation of histone 
H3 isoforms using an acid-urea gel prior to mass spectrometry analysis. While this 
previous study provided valuable kinetic information regarding Gcn5 site-specificity by 
determining the rates of acetylation on individual lysine residues, it may have been 
difficult to accurately distinguish the order of H3K9 and H3K23 acetylation without 
initially purifying distinct acetylation states. 
A second possibility that may account for the differences observed between our 
work and the previous Gcn5 site-specificity study may be due to the form of Gcn5 being 
utilized in the in vitro reactions. The first study used monomeric Gcn5 alone while our 
study used the Gcn5-Ada2-Ada3 subcomplex, which could account for slight differences 
in Gcn5 HAT site specificity since Ada2 and Ada3 were previously shown to affect Gcn5 
enzymatic activity (116, 118). For example, previous studies have compared enzymatic 
HAT activity of monomeric Gcn5, the Gcn5-Ada2-Ada3 subcomplex, the intact ADA 
complex (0.8 MDa), and the intact SAGA complex (1.8 MDa) which showed an 
increased repertoire of acetylated histone H3 lysine residues as Gcn5 was able to 
interact with its binding partners and complex subunits (112, 115, 116). Additionally 
distinct acetylation kinetics were observed between the ADA and SAGA complexes 
indicating that Gcn5 enzymatic activity is regulated in part by the protein factors with 
which it interacts. 
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It must also be considered, that in addition to biologically relevant enzymatic 
subcomplexes, using higher-ordered nucleosomal substrates is ideal for performing in 
vitro HAT reactions. Because Ada2 and Ada3 contain nucleosome and DNA interacting 
domains it is critical to examine HAT activity on histone H3 in the context of the 
nucleosomal substrate. We observed a variation in acetylation rate between free 
histone H3 and histone H3 in the context of the histone octamer. While our Gcn5 
subcomplex site specific analysis was performed on free histone H3, it is crucial to test 
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Chapter 3: The Gcn5 bromodomain impacts 
catalytic acetyltransferase activity 
 
The majority of this research was originally published in Molecular 
and Cellular Proteomics. Anne M. Cieniewicz, Linley Moreland, 
Alison E. Ringel, Samuel G. Mackintosh, Ana Raman, Tonya M. 
Gilbert, Cynthia Wolberger, Alan J. Tackett, and Sean D. 
Taverna. The Bromodomain of Gcn5 Regulates Site Specificity of 
Lysine Acetylation on Histone H3. Molecular and Cellular 
Proteomics. 2014; 13: 2896-2910. © The American Society for 
Biochemistry and Molecular Biology. (111) 
 
3.1 Introduction 
The acetyl-lysine binding bromodomain motif is evolutionarily conserved and 
often found in HATs and HAT associated complexes (32, 33, 41, 139, 140). The 
bromodomain of Gcn5 and the highly homologous PCAF bromodomain (Figure 16) 
have been shown to interact with acetylated histone lysine residues H3K9ac, H3K14ac, 
H3K36ac, H4K16ac, and H4K8ac  (40-42, 92, 139, 141, 142). Additionally, the 
Gcn5/PCAF bromodomain has been shown to interact with acetylated lysines on non-
histone proteins such as K50ac on HIV-1 Tat  (143, 144). The Gcn5 bromodomain has 
been found to contribute to chromatin remodeling, cooperative nucleosome acetylation, 
and anchoring complexes to chromatin (141, 145).  
 Studies that introduced point mutations into the yeast Gcn5 bromodomain which 
disrupted binding to acetylated lysine residues led to a decrease in Gcn5 dependent 
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  transcription and histone acetylation at in vivo promoters (13, 73, 145-148). 
Additionally, it was observed that bromodomain mutations that disrupted acetyl-lysine 
binding led to an overall decrease of nucleosome acetylation in vitro. Specifically, the 
bromodomain mutation of Y413 in yeast Gcn5 (or homologous Y809 in PCAF) disrupts 
acetyl-lysine binding and was previously introduced into the Gcn5 subcomplex identified 
bromodomain-dependent cooperativity of acetylation on nucleosome substrates, 
although alterations in site specificity were not identified (139, 141, 145). Importantly, 
this mutation maintains the structural integrity of the bromodomain, does not alter the 
stoichiometry of the Gcn5 subcomplex, and has been shown alter acetylation at Gcn5-
targeted promoters in vivo  (139, 141, 145) (Figure 17A). A double bromodomain 
mutation within the ZA loop has also been studied in Gcn5. Mutation of P371 and M372 
has been shown to completely destabilize the structural integrity of the bromodomain  
(149) (Figure 17B).  
Although these previous studies suggest that the Gcn5 bromodomain may 
contribute to proper acetylation of Gcn5 HAT activity, the impact of the bromodomain 
acetyl-lysine binding function on enzymatic HAT activity remains poorly characterized. 
Specifically, we aim to understand how overall HAT activity and site specificity of Gcn5 
are altered upon disruption of the bromodomain acetyl-lysine binding function. We 
hypothesized that the bromodomain plays a role in directing the site specificity of Gcn5. 
To test this, we generated bromodomain point mutants in the Gcn5 subcomplex. We 
generated a Gcn5 complex that contained the Y413A mutation, which disrupts acetyl-
lysine binding functions while maintaining bromodomain structural integrity and showed 
that this mutation disrupts the ability of the Gcn5 bromodomain to bind to acetylated 
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  lysine residues (Figures 17A, 18). Secondly, we introduced the double P371T/M372A 
mutation into the Gcn5 subcomplex to entirely destabilize the bromodomain (Figure 
17B). These bromodomain-mutated complexes were used to assess the impact of the 
Gcn5 bromodomain on overall HAT activity and site specific acetylation using our 
combined acid-urea gel and mass spectrometry approach. 
Further insight of how bromodomains or other histone readers can affect 
chromatin-templated catalytic activities may yield greater understanding into 
mechanisms of histone PTM crosstalk. In-depth characterization of the biologic role of 
the Gcn5 bromodomain and how it may impact enzymatic activity could provide 
important parameters for epigenetic drug design. Because the human homolog of Gcn5 
is found to be mutated in several diseases and with the success of BET bromodomain 
inhibitors, better understanding of the Gcn5 bromodomain could refine its use as a 
potential drug target. 
 
3.2 Methods 
3.2A Cloning, recombinant expression, and purification of Gcn5 
subcomplex bromodomain mutants 
The Gcn5 Y413A bromodomain mutant and the Gcn5 P371T/M372A double 
point mutant were generated using QuikChange site-directed mutagenesis (Stratagene) 
on the plasmid containing full-length ADA3. The expression of full-length 
Gcn5/Ada2/Ada3 subcomplex and subsequent purification with Talon metal affinity resin 
(Clontech) and a FPLC SourceQ column (GE Healthcare). Concentrations of the 
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  recombinant wildtype and mutant Gcn5/Ada2/Ada3 subcomplexes were normalized 
using SDS-PAGE gels and Coomassie blue staining. 
3.2B Cloning, recombinant expression, and purification of the Gcn5 
bromodomain 
Wild type, Y413A, and P371T/M372A yeast Gcn5 bromodomains (residues 329-
438 of Gcn5p) were cloned from the respective pST44-yAda3t2HISx3-yAda2x3-
yGcn5x5 polycistronic vectors containing yeast GCN5, ADA2, and ADA3 from WT, 
Y413A, and P371T/M372A. Bromodomains were cloned into an N-terminal Thioredoxin-
HIS6-S•tag tag (pET32a vector, Millipore). Proteins were recombinantly expressed in 
chemically competent BL21 E. coli (Invitrogen) after overnight induction with 1 mM IPTG 
at 20 °C in LB medium. Bacteria were pelleted, freeze-thawed and resuspended in 
purification buffer (50 mM Tris pH 7.5, 500 mM NaCl, 40 mM imidazole, 10% glycerol, 2 
mM B-ME, 1 mM PMSF, 2 mM benzamidine) and lysed by sonication (Branson). Lysate 
was incubated with Ni-NTA agarose resin (Invitrogen) for least 1 hour at 4 °C. Resin 
was washed with purification buffer and protein was eluted with purification buffer 
containing 150 mM imidazole. Protein was aliquotted and flash frozen in liquid nitrogen 
and stored at −80 °C. 
3.2C Bromodomain peptide pull-down assays 
Peptide pull-downs were essentially performed as in Taverna et al., 2007 (10), 
with the following modifications. Briefly, streptavidin-coupled dynabeads (20 ml per 
sample) (Invitrogen M-280) were incubated with biotinylated histone peptides (1 mg per 
sample) in PBS, and washed in PBS. Peptide coated beads were then incubated with 
purified bromodomain (1 mg) in the presence of BSA competitor (1 mg) in binding buffer 
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(20 mM HEPES pH 7.9, 100 mM NaCl, 0.2% Triton X-100, 0.5 mM DTT, 10% glycerol) 
for 3 hrs at room temperature. Beads were washed 3 times for 5 min each with high-salt 
wash buffer (20 mM HEPES pH 7.9, 300 mM NaCl, 0.2% Triton X-100, 0.5 mM DTT, 
10% glycerol), and 1 time with low-salt wash buffer (4 mM HEPES pH 7.9, 20 mM 
NaCl). Peptide bound protein was eluted off beads with boiling 1X SDS-PAGE sample 
buffer, then resolved on 12% SDS-polyacrylamide gels, transferred to PVDF, and 
probed with antibodies recognizing S-tag (ab18588, Abcam, 1/500) and Streptavidin-
HRP (Molecular Probes S-911, 1/1000). Input lanes represent 0.1% bromodomain 
protein used in the pull-down.  
H3 peptides: 
H3 1-20 unmod biotin: ARTKQTARKSTGGKAPRKQL-K(Biotin)-NH2  
H3K14ac 1-20 biotin:  ARTKQTARKSTGGK(ac)APRKQL-K(Biotin)-NH2 
3.2D Nucleosome reconstitution 
 Recombinant histones from Xenopus laevis were expressed in E. coli, purified 
from inclusion bodies, and assembled into histone octamers as described previously 
(150).  DNA for recombinant mononucleosomes was obtained by EcoRV digestion of 
pST55-16xNCP601, courtesy of Dr. Song Tan (Penn State, PA), which contained 
sixteen tandem copies of a 147 bp fragment with the 601 positioning sequence  (151).  
Prior to reconstituting nucleosomes, the 147 bp DNA fragments were purified as 
described previously  (152). Nucleosome core particles were assembled using the salt 
gradient dialysis method followed by HPLC-purification on a TSKgel DEAE-5PW column 
with 13 µm particle size (34). Nucleosomes were dialyzed into low-salt buffer (10 mM 
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Tris-HCl pH 7.5, 5 mM KCl, 1mM DTT) and concentrated to 25-50 µM for storage at 
4°C, where they were used within a month of preparation. 
3.2E In vitro histone acetyltransferase assays  
See Chapter 2.2 
 HAT assays run over a time course were first incubated at 30˚C for 2 minutes 
prior to adding enzymatic subcomplex at a concentration of 50 nM except for Time 0 
which was flash frozen immediately upon addition of enzyme. Reactions were carried 
out for the respective time course at 30˚C and flash frozen and lyophilized upon 
completion. A non-enzymatic reaction was carried out for 8 hours at 30˚C to control for 
spontaneous acetyl CoA acetylation or histone degradation. 
Assays containing nucleosomal substrates consisted of 0.55 µM nucleosome, 
150 nM of either WT or Y413A subcomplex, and 30 µM acetyl CoA carried out in a total 
of 30 µL reaction volume. Reactions were run for 30 mins at 30˚C and flash frozen upon 
completion. ADA subcomplex was omitted from the non-enzymatic negative controls. 
3.2F Cloning, expression, and chemical acetylation of histone H3 
point mutants 
The pET3a vector containing yeast histone H3 sequence was obtained courtesy 
of Dr. Gregory Bowman (The Johns Hopkins University, Baltimore, MD). Both H3K14R 
and H3K23R were generated using QuikChange site-directed mutagenesis 
(Stratagene). Histones were expressed, purified from inclusion bodies, and further 
purified over HPLC. To obtain maximally acetylated histone H3 control recombinant S. 
cerevisiae histones were subjected to in vitro acetylation as previously outlined (119).  
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Acetylated histones were purified and desalted using HPLC purification, and fractions 
were combined, flash frozen, and lyophilized. 
3.2G Western blot analysis of histone H3 acetylation 
Histone H3 samples were resolved by SDS PAGE and were transferred to a 
PVDF membrane using a semi dry transfer system. Membranes were blocked overnight 
in 5% milk at 4˚C and washed in Tris Buffer Saline (TBS).  Primary antibody anti-H3ac 
(Millipore, 1/5,000) was diluted in 1% milk in TBS and 0.1% Tween (TBST) for HAT 
assay. For histone mutant western blots anti-H3K14ac (ab52946, Abcam, 1/5000); anti-
H3K18ac (Active Motif 39130, 1/10,000); anti-H3K23ac (Active Motif 39132, 1/20,000) 
were used. Primary antibody was applied for 1 hour at room temperature followed by 
washing in TBST.  Goat anti-rabbit IgG-horseradish peroxidase secondary antibody 
(Amersham Biosciences) was diluted to 1/4000 in 1% milk and TBST and applied for 1 
hour at room temperature and washed in TBST.  Blots were developed using Pierce 
ECL Western Blotting Substrate (ThermoScientific) and exposed using film. 
3.2H Generation and growth of yeast strains 
Δgcn5 and Δgcn5Δyng1 background yeast strains were obtained from the lab of 
Dr. Brian Strahl University of North Carolina Chapel Hill. WT Gcn5 and Y413A Gcn5 
plasmids were introduced into each strain. Yeast were grown in His drop out media and 
spun down and pelleted with the supernatant removed. Yeast strains were generated by 
Ana Raman. 
3.2I Acid extraction of histones from yeast 
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Pellets were frozen and thawed on ice and resuspended in 0.5 mL of 20% ice 
cold TCA. 0.5mLs of glass beads were added and vortexed four times for 30 seconds 
each in the cold room. Lysate was transferred to a fresh Eppendorf tube. Beads were 
washed twice with 0.5 mL of %% ice cold TCA and the washes were combined with the 
lysates. Precipitated protein was spun down at 3krpm for 10 mins at 4°C. Supernatant 
was removed and pellets were resuspended in 200 uL of 1X sample buffer in which 50 




3.3A Mutation of the bromodomain disrupts lysine acetylation on 
histone H3 
To better understand how the loss of Gcn5 bromodomain function impacts Gcn5 
subcomplex HAT activity, in vitro HAT reactions were resolved on acid-urea gels 
comparing the histone H3 acetylation patterns generated by increasing concentrations 
of WT vs. Y413A Gcn5 subcomplexes or WT vs. P371T/M372A Gcn5 subcomplexes 
(Figures 19A, 19B). At enzyme concentrations greater than 50 nM the pattern of 
histone H3 acetylation became noticeably altered between the WT and bromodomain 
mutant Gcn5 subcomplexes. A relative lag in acetylated histone H3 reaction 
intermediates was observed in Y413A and P371T/M372A HAT reactions when 
compared to histone H3 acetylated by the WT Gcn5 subcomplex. Notably, at higher 
enzyme concentration (200 nM) bromodomain mutant subcomplexes generated an 
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  enrichment in a di-acetylated histone H3 isoform instead of progressing to a hexa-
acetylated state formed in the WT reaction. Because the staining intensity of the hexa-
acetylated histone H3 band (band 6) in the WT reaction was relatively comparable to 
the di-acetylated histone H3 band (band 2) in the Y413A reaction, it can be inferred that 
the Gcn5 bromodomain contributes a 3-fold increase in histone H3 acetylation. Taken 
together, these results suggest that when the Gcn5 bromodomain is defective in acetyl-
lysine binding, overall histone H3 acetylation is decreased. 
Having established that the bromodomain contributes to changes in histone H3 
acetylation pattern over increasing Gcn5 subcomplex enzyme concentrations, we next 
wanted to further examine how overall acetylation was affected in WT and Y413A 
reactions. Therefore, we investigated the evolution of differential acetylation patterns in 
kinetic time course experiments between the WT and bromodomain mutant 
subcomplexes at a concentration of 50 nM enzymatic subcomplex (Figures 20A, 20B). 
Consistent with observed acetylation differences using increasing enzyme 
concentrations, we found a reduction in total histone H3 acetylation with the Y413A 
Gcn5 subcomplex at later time points of 60 min, 4 hr, and 8 hr. Densitometry 
quantitation of histone H3 band intensity resolved on acid-urea gels underscored the 
differences in acetylation pattern between WT and bromodomain mutant Gcn5 
subcomplexes (Figure 20B). Interestingly, at earlier time points of 1 min, 5 min, and 15 
min the Y413A Gcn5 subcomplex exhibited more robust acetylation activity on initial 
lysine events. The formation and progression to mono, di, and tri-acetylated histone H3 
states occurred faster in the Y413A reactions when compared with the WT reaction. 
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  3.3B The Gcn5 bromodomain regulates site specificity of acetylation 
on histone H3 
Because our acid-urea gel analysis revealed that disruption of Gcn5 
bromodomain acetyl-lysine binding function resulted in an altered histone H3 acetylation 
pattern we sought to examine differences in acetylation abundance on individual lysine 
residues and determine if the observed Gcn5 subcomplex site specificity of H3K14 > 
H3K23 > H3K18 = H3K9 > H3K27 > H3K36 was at all disrupted when the bromodomain 
was mutated. We first used semi-quantitative mass spectrometry on histone H3 
resolved via SDS-PAGE comparing the overall acetylation levels at individual lysine 
residues generated by either WT or Y413A Gcn5 subcomplexes (Figure 21). We found 
that the Y413A Gcn5 subcomplex was able to acetylate H3K14 and H3K23 to WT 
levels. However, the Y413A Gcn5 subcomplex demonstrated reduced acetylation on 
residues H3K9 and H3K18. Acetylation abundance at H3K27 and H3K36 were 
undetectable by mass spectrometry when histone H3 was resolved on SDS-PAGE.  
While resolution over SDS-PAGE and combined mass spectrometry analysis 
allowed us to determine total acetylation abundance on individual lysine residues, 
insight into site specificity requires resolution of differentially acetylated states over an 
acid-urea gel. Using an acid-urea gel we are able to determine any alterations in 
acetylation pattern between the WT and Y413A subcomplex reactions (Figures 22A, 
22B). To gain understanding into bromodomain related changes in site specificity, we 
compared WT HAT reactions with that of the Y413A bromodomain mutant reactions 
using the combined acid-urea gel and mass spectrometry approach (Figures 22, 23, 
24). In both the WT and Y413A reactions we found the same six histone H3 lysine 
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  residues were acetylated. However, although H3K14ac, H3K23ac, and H3K9ac were 
the preferred lysines acetylated by the WT and with both mutant subcomplexes, 
significant differences were detected when we compared acetylation levels among 
downstream lysines. In contrast to the pattern of acetylation observed with the WT 
subcomplex where H3K18ac occurred in the 3rd acetylation states, in both 
bromodomain mutants H3K18ac did not occur until the 5th and 6th acetylation states. 
Furthermore, H3K27ac and H3K36 acetylation generated from the bromodomain 
mutants occurred earlier when compared histone H3 isoforms from the WT reaction.  
We sought to determine if this observed effect could be repeated with additional 
bromodomain mutations other than Y413A, and therefore tested the disruptive 
P371T/M372A Gcn5 bromodomain mutation to determine if this would result in the 
same disruption of histone H3 site-specificity. We resolved the WT and P371T/M372A 
reactions over an acid-urea gel and excised the bands for mass spectrometry analysis 
(Figure 25A). Interestingly the histone H3 acetylation pattern generated by the 
P371T/M372A resembled that generated by the Y413A subcomplex in that there 
appeared to be an accumulation of mono and di-acetylated states. Quantitative mass 
spectrometry revealed that histone H3 lysines K9, K14, and K23 were unaffected by the 
P371T/M372A bromodomain mutation, while the site specificity of lysines K18, K27, and 
K36 were affected in strikingly similar manner as that of the nondisruptive Y413A 
mutation (Figure 25B). 
3.3C Bromodomain dependent site specific acetylation on 
nucleosomal substrates 
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   Having established a relationship between the Gcn5 bromodomain and site 
specific acetylation on free histone H3 we aimed to examine how the bromodomain 
might affect HAT activity when using the biologically relevant nucleosomal template. We 
analyzed WT and Y413A HAT reactions using antibodies against histones and histone 
H3 lysine specific acetylation events that occurred within the nucleosome. Consistent 
with previous studies, the Gcn5 subcomplex acetylation within the nucleosome occurred 
on histone H3 with a single lysine acetylation on both histone H4 and histone H2B 
(Figure 26A). Just as we observed with free histone H3, acetylation on nucleosomal 
histone H3 contained a total of 6 acetylation sites with strikingly diminished overall 
acetylation in the Y413A bromodomain mutant. In the Y413A HAT reaction the majority 
of histone H3 resolved as a mono (band 1) or di-acetylated (band 2) species, instead of 
progressing to a hex-acetylated state observed in the WT reaction. The effects of the 
bromodomain on Gcn5 catalytic HAT activity appeared to be specific to histone H3 as 
acetylation of H2B and H4 remained unchanged regardless of bromodomain acetyl-
lysine binding function. 
To determine how nucleosomal histone H3 acetylation on individual lysine 
residues was affected when the bromodomain was disrupted, acetyl-lysine specific 
antibodies were used to compare the distribution of site specific acetylation between 
WT and Y413 reactions (Figure 26B). H3K14ac was found to be enriched in lower 
acetylation states catalyzed by the Y413A mutant, suggesting a loss of acetylation 
processivity relative to the WT subcomplex. The most striking observation was the 
comparison of H3K18ac abundance and distribution between the WT and Y413A HAT 
reactions. H3K18ac was nearly undetectable when the bromodomain acetyl-lysine 
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  binding function was disrupted in the Y413A Gcn5 subcomplex indicating the 
acetylation of K18 is heavily dependent on a functional Gcn5 bromodomain. H3K27ac 
remained detectable at in both WT and Y413A reactions, however this modification was 
now enriched in lower acetylation states in the Y413A reaction compared with that of 
the WT reaction, which is consistent with the observation on free histone H3 utilizing 
mass spectrometry analysis.  
3.3D Gcn5 acetylation of H3K18 is dependent on H3K14ac in a 
bromodomain-mediated manner 
Because Gcn5 acetylation of H3K18 is dependent on the acetyl-lysine binding function 
of the bromodomain, we aimed to uncover mechanistic insight into how the 
bromodomain facilitates H3K18ac. We hypothesized this could be due to bromodomain-
mediated crosstalk between a previously deposited lysine residue and proper 
acetylation of K18 acetylation. Because H3K14 and H3K23 are the first lysines 
acetylated by the Gcn5 subcomplex and their acetylation as independent of the Gcn5 
bromodomain, we reasoned that the bromodomain may be binding H3K14ac and/or 
H3K23ac and thereby facilitating proper acetylation of K18ac via the Gcn5 HAT domain. 
To test whether H3K18ac is affected when H3K14 or H3K23ac is unable to be 
acetylated, we generated histone H3 point mutants where we obtained clones for 
H3K14R H3K23R (Figure 27A). Because arginine is structurally similar to lysine and 
also has a positive charge, this mutation would be least detrimental on histone structure 
and protein-protein interactions. We generated S. cerevisiae H3K14R and H3K23R 
point mutations to test in in vitro HAT assays. Using these substrates we validated the 
specificity and reactivity of histone acetyl-lysine antibodies against H3K14ac, H3K2ac 
	   67	  
	   68	  
	  and H3K18ac. While PTM specific antibodies are very useful tools in determining site 
specific modifications, they have several disadvantages associated with them. Issues 
with cross-reactivity, broad epitope specificity, and being unable to provide a 
quantitative measure have encouraged the use of mass spectrometry and proteomics 
techniques for identifying and measuring histone PTMs (153, 154). We chemically 
acetylated these substrates with acetic anhydride so that every available lysine residue 
on these proteins was acetylated. Arginines are not acetylated in this treatment, and 
therefore anti-H3K14ac and anti-H3K23ac antibodies should not recognize H3K14R and 
H3K23R point mutants, which was verified by western blot (Figure 27B).   
We subjected each histone H3 substrate, WTH3, H3K14R, H3K23R to an in vitro 
HAT reaction with the WT Gcn5 subcomplex. HAT reactions were resolved on acid-urea 
gels to compare the pattern of overall acetylation among each substrate (Figure 28). In 
both H3K14R and H3K23R histone mutants, only five lysines were detectable 
acetylated due to the loss of either H3K14 or H3K23 as a Gcn5 lysine target. The 
acetylation rate was evident as the progression from an unacetylated to a 
hyperacetylated state. We observed acetylation rates to be reduced in both histone K to 
R point mutants relative to WT histone H3.The H3K14R mutant was acetylated at a 
substantially slower rate, indicated by a greater intensity in the lowest, unacetylated 
histone H3 band (band 0).  
To determine whether H3K14 of H3K23 acetylation might affect K18 acetylation 
levels, we utilized acetyl-lysine specific antibodies on HAT reactions, which were 
resolved on either SDS-PAGE, or acid-urea gels. Acetylation levels were then 
compared using antibodies that have been tested and verified against hyperacetylated 
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  histone substrates to ensure cross reactivity was not occurring and the K to R mutation 
did not disrupt antibody epitope recognition. Western blots using anti-H3K18ac, anti-
H3K14ac, and H3K23ac were first performed on SDS-PAGE resolved HAT reactions to 
determine the total acetylation level catalyzed by the Gcn5 subcomplex on WT and K to 
R mutant histone H3 substrates (Figure 29A). Here we observed a marked decrease of 
K18ac on the H3K14R, whereas H3K18ac was minimally affected o the H3K23R 
substrate. When these reactions were resolved on acid-urea gels and subjected to the 
same Western blot analysis, a striking decrease of H3K18ac was again observed on the 
H3K14R mutant relative to WTH3 and H3K23R substrates (Figure 29B). Here, 
H3K18ac was only observed on the H3K14R histone in the highest acetyl-H3 band 
(band 5). Together, these data suggest that acetylation of H3K18by the Gcn5 
subcomplex is dependent upon the presence of an acetylatable lysine at H3K14, but not 
H3K23. 
3.3E H3K18ac is dependent upon Gcn5 bromodomain acetyl lysine 
binding function in vivo 
Because our in vitro data revealed a striking decrease in H3K18 acetylation when 
the Gcn5 bromodomain acetyl-lysine binding function was disrupted, we wanted to 
determine if this effect also occurred in vivo within the context of the cell. We generated 
S. cerevisiae yeast strains that contained either WT or Y413A Gcn5 (Figure 30A). WT 
Gcn5 or Y413A Gcn5 plasmids were introduced into both ΔGcn5 and ΔGcn5ΔYng1 
background strains. A ΔGcn5ΔYng1 background was used because in vivo lysine 
acetylation of histone H3 is catalyzed by both Gcn5 and the HAT NuA3-complex HAT, 
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  Sas3 (155, 156). Yng1 is a subunit of NuA3, required for NuA3 localization to 
chromatin, and necessary for proper NuA3 acetylation of histone H3 (34, 37).  By 
deleting Yng1 we posited that Sas3 would minimally acetylate histone H3, and Gcn5 
acetylation can be independently assessed without any redundant HAT activity by 
NuA3. 
Histones were isolated from each strain and resolved over SDS-PAGE gels. 
Histone H3 acetyl-lysine specific antibodies were used to compare global acetylation 
levels at individual lysine residues (Figure 30B). In both the ΔGcn5 and ΔGcn5ΔYng1 
background strains we observed a striking decrease in global K18ac in the Y413A Gcn5 
bromodomain mutant strain. Global H3K14ac and H3K23ac levels were unaffected by 
the Y413A Gcn5 bromodomain mutation. These results indicate that the global 
acetylation of H3K18ac levels is dependent upon the Gcn5 bromodomain in vivo.  
 
3.4 Discussion 
3.4A General discussion 
We found that ablation of the acetyl-lysine binding function of the Gcn5 
bromodomain diminished the amount of total acetylation on and disrupted the order in 
which lysines were acetylated on free and nucleosomal histone H3. Ultimately, Gcn5 
subcomplex site specific acetylation of H3K14 and H3K23 was show to be independent 
of bromodomain function, whereas downstream acetylation of lysines H3K9, H3K18, 
H3K27, and H3K36 was altered upon mutation of the Gcn5 bromodomain (Figure 31A). 
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  Previously, the effect of the Gcn5 bromodomain on catalytic HAT activity and site 
specificity on histone proteins has been poorly characterized. In vivo studies have 
shown that Gcn5 bromodomain point mutants, including the Y413A and the 
P371T/M372A used in our analysis, suggest that the bromodomain acts to regulate HAT 
activity at Gcn5-targeted promoters and acts to maintain proper nucleosome remodeling 
(32, 73, 74, 92, 145, 149, 157). The site specificity of the Gcn5 subcomplex, especially 
concerning that of H3K18 acetylation, was similarly altered utilizing two independent 
bromodomain mutants. These mutations included a non-disruptive Y413A mutant that 
ablated Gcn5 bromodomain acetyl-lysine binding while maintaining the structural 
integrity of the bromodomain. Additionally, a disruptive P371T/M372A bromodomain 
mutant introduced in the ZA loop has been shown to disable the bromodomain and in 
turn ablate acetyl-lysine binding. However, when purifying the Gcn5 subcomplex with 
the structurally disruptive P371T/M372A mutation we observed an uneven stoichiometry 
in the complex members where approximately a 2-fold increase of Ada3 co-purified with 
the subcomplex. We reasoned that the disruptive bromodomain mutation may have 
affected the structural interaction of Gcn5 with its binding partners resulting in uneven 
stoichiometry of the trimeric subcomplex. Given the changes we observed with both our 
disruptive (P371T/M372A) and nondisruptive (Y413A) Gcn5 bromodomain point 
mutants, additional bromodomain mutations to residues such as Gcn5 Y364 and N407, 
which are predicted by structural studies to be important for acetyl-lysine binding, might 
display a similar loss in H3K18ac (42, 92, 143, 157). Furthermore, the interaction of the 
Gcn5 bromodomain with acetyl-lysine residues has been suggested to underlie 
cooperative acetylation of Gcn5 complexes on nucleosomal substrates (145). Our 
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results confirm the bromodomain regulates overall histone H3 acetylation and is 
required for site specific acetylation events by Gcn5. 
The Gcn5 bromodomain clearly altered the order of acetylation on H3K18, 
H3K27, and H3K36. Acetylation events on H3K14, H3K23 and possibly H3K9 are likely 
dominated by residues surrounding the HAT domain of Gcn5, while downstream 
acetylation events of H3K18, H3K27, and H3K36 may be aided by bromodomain 
interaction with previously deposited acetyl-lysine modifications. Our data and several 
previous studies have confirmed that H3K14 is the preferred lysine acetylated by Gcn5 
and H3K14ac has also been shown to be a binding target of the Gcn5 bromodomain 
(79-81, 113). Our data showed that Gcn5-catalyzed H3K18ac was greatly diminished 
under conditions when the Gcn5 bromodomain was impaired in addition to HAT 
reactions using the H3K14R substrate when H3K14 could not be acetylated. Therefore, 
we propose a reader/writer model where Gcn5 catalyzes H3K14ac where the Gcn5 
bromodomain in turn binds to the H3K14ac mark thus stimulating Gcn5 HAT activity on 
H3K18 (Figure 31B). While, our study provides valuable insight into the interplay 
between the Gcn5 HAT and bromodomain in terms of histone H3 site specificity, several 
mechanistic questions still remain. Whether the Gcn5-mediated crosstalk of H3K14ac 
and H3K18ac occurs on the same histone H3 protein or on whether the bromodomain 
might engage H3K14ac on one histone tail and promote H3K18ac on a different histone 
H3 molecule is currently unknown. Additionally, while H3K23ac did not appear to affect 
K18ac levels, further testing would be useful as to how downstream acetylation events 
other than K18ac, such as H3K27ac and H3K36ac might be affected when H3K23 or 
H3K14 are unable to be acetylated as in our H3 K to R mutant HAT assays. 
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   While ablation of Gcn5 bromodomain acetyl-lysine binding function was shown to 
have a profound affect on histone H3 acetylation, Gcn5 acetylates many non-histone 
substrates that are involved in several biological pathways. Gcn5 acetylation of the 
transcriptional co-activator PGC-1α, has been shown to prevent hepatic 
gluconeogenesis (Figure 32A)  (76, 77). Gcn5 HAT activity is necessary for cell cycle 
progression as acetylation of CDC-6 at three lysine residues ensures proper S-phase 
progression (158). Understanding if and how the Gcn5 bromodomain might affect 
catalytic HAT activity on these and other non-histone substrates could provide insight 
on Gcn5 function in endogenous molecular pathways.  
3.4B The function and deposition of H3K18 acetylation in vivo 
Our findings suggested interplay between the Gcn5 bromodomain reader 
function and its catalytic writer HAT function that showed to have the greatest affect on 
histone H3K18 acetylation. Crosstalk among histone PTMs such as acetylation, 
methylation and phosphorylation is gaining wide appreciation as a regulatory 
mechanism to foster or prevent interactions among chromatin effector complexes and 
substrates. It has been shown that histone H3 phosphorylation of threonine 11 has been 
shown to reduce the ability of Gc5n to acetylate H3K14 (159). The yeast histone 
acetyltransferase complex, NuA3, has been shown to bind H3K4 trimethylation via its 
PHD finger of its Yng1 subunit and then promotes the acetylation of H3K14 via its HAT 
subunit, Sas3 (34, 35, 37). Similarly, Gcn5-containing complexes, such as ADA and 
SAGA, are also able to engage H3K4me3 through the subunit Sgf29 that contains a 
tandem tudor domain (88, 160). However, the impact of how H3K4me3 binding affects 
Gcn5 HAT site specificity is described in further detail in Appendix section A.2.  
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   In the context of prior in vivo studies using bromodomain mutations, our work 
suggests the existence of endogenous pathways that may target the acetyl-lysine 
binding capacity of the bromodomain as a means to affect and regulate catalytic HAT 
activity, especially that of H3K18. Relevant to our findings that K18ac acetylation levels 
decrease upon disruption of Gcn5 bromodomain both in vitro and in vivo, it has been 
previously reported that deletion of Gcn5 completely abolishes global H3K18 acetylation 
in yeast strains (160) (Figure 31C). Levels of histone H3K14ac and H3K9ac were 
unaffected when Gcn5 was deleted, which could be the result of these lysine residues 
being redundant targets by multiple HAT enzymes such as NuA3 (160).   
However, regulation of H3K18ac in the context of mammals and humans may be much 
more complicated than in yeast as multiple mammalian HATs have been reported to 
acetylate H3K18, including Gcn5, PCAF, P300, and CBP (90, 91, 161, 162). One study 
examined the impact of HAT deletions on histone H3 lysine specific acetylation and 
found that deletion of GCN5/PCAF paralogues resulted in decreased H3K9ac, while 
deletion of P300/CBP decreased global levels of H3K27ac and H3K18ac (91). However, 
additional studies report a stronger correlation of Gcn5/PCAF with H3K18ac in 
mammals. A recent report showed H3K18ac levels were regulated by PCAF at distinct 
inflammatory genes in renal cells  (90). Furthermore, another study linked histone H3 
lysine acetylation levels with the subunit Sgf29, which acts within the same HAT module 
as the Gcn5/PCAF, Ada2, and Ada3 subcomplex (160).  Interestingly, when Sgf29 is 
knocked out in yeast or knocked down in human cell lines, the effects on global H3 
acetylation levels of individual lysine residues very closely resembles the patterns we 
observed with our Gcn5 Y413A bromodomain mutation (160). Specifically, when 	  Sgf29 
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as a whole or when either of the tandem tudor domains was deleted, H3K18ac levels 
were significantly decreased on a global level (160). Because the tandem tudor domain 
of Sgf29 and the bromodomain of Gcn5 are found within many of the same complexes, 
perhaps they have a dual function that contributes to complex avidity in anchoring to 
chromatin and affecting enzymatic HAT activity. Determining which complex is 
responsible for K18ac could vary in a manner specific to cell-type, pathway, or gene, 
which warrants greater understanding into the site specificity of mammalian HATs. 
Interestingly, Gcn5, PCAF, P300, and CBP all contain bromodomains in addition to their 
HAT domains. It would be interesting to see if bromodomain acetyl-lysine binding 
ablation of these additional HATs would have an impact on catalytic activity in a manner 
similar to that which we observed with Gcn5 (Figure 32B). 
3.4C The Gcn5 bromodomain as a potential therapeutic target 
Because Gcn5 has been implicated in several disease states such as diabetes, 
spinocerebellar ataxia, and cancer, it is therefore poised as potential therapeutic target 
(60, 62, 76, 77, 105). However, the enzymatic HAT domain of Gcn5 participates in 
widespread acetylation and general transcription of nearly the entire transcribed 
genome and thereby inhibiting Gcn5 catalytic function would be extremely detrimental to 
the cell (64, 85, 100). This is made evident as deletion of the Gcn5 HAT domain 
resulted in embryonic lethality (64, 100). Thereby, the Gcn5 HAT domain would present 
itself as a poor drug target due to the very fundamental roles it plays in the cell (Figure 
33A). However, with the success of recent bromodomain inhibitors, such as JQ1 and I-
BET that inhibit the BET bromodomains, the Gcn5 bromodomain could hold promise as 
a drug target that could be exploited by small molecule inhibition. Our study showed that 
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Gcn5 bromodomain disruption did not lead to a widespread acetylation decrease in all 
Gcn5 lysine targets, as would be the case with Gcn5 HAT inhibition, but instead only a 
single lysine, H3K18ac, was significantly decreased (Figure 33B). Therefore inhibiting 
the Gcn5 bromodomain as opposed to the HAT domain would provide a more targeted 
decrease in histone H3 acetylation, and would be expected to have less detrimental 
affects than abolishing global widespread Gcn5 acetylation. 
When considering small molecule inhibitors that might block the bromodomain, it 
would be likely that an inhibitor against the Gcn5 bromodomain could work to also 
inhibit the highly homologous bromodomain of the Gcn5 paralogue, PCAF. The 
bromodomains of PCAF and Gcn5 share 95% similarity, and while Gcn5 is conserved 
from yeast through humans, the PCAF gene generated from a duplication and 
divergence of the GCN5 gene (47, 89, 99). PCAF also has implications in disease and 
has been linked with H3K18ac in a recent study. This group found that K18ac linked 
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 Chapter 4: Tools for studying in vitro activity of 
histone modifying enzymes 
 
 
4.1 Introduction  
Exploiting certain eukaryotic model organisms has proved extremely useful for 
elucidating basic biological ramifications of epigenetic phenomena, like the fundamental 
roles of histone modifications and chromatin interacting proteins. For example, studying 
the chromatin of the single-celled prokaryote Tetrahymena thermophila, which has both 
an actively transcribed euchromatic nucleus and a heterochromatic nucleus, led to the 
discovery of Gcn5 as a transcriptional activator and novel histone modifications, such as 
H3K23 trimethylation (57, 163). Furthermore, genetic manipulation and mutation 
analysis in S. cerevisiae and S. pombe have provided unprecedented insight into the 
biological contributions of individual histone residues and subunit architecture of effector 
protein complexes (164, 165). However, in vitro characterization of histone binding 
protein complexes lends valuable insight into chromatin interactions, enzymatic activity, 
genome localization and pathway regulation. Advances in technology such as improved 
sensitivity in proteomics and DNA sequencing have greatly increased our understanding 
of epigenetic mechanisms as well.  
While the past 20 years have seen hallmark studies and technological 
advancements in the field of epigenetics, developing biologically relevant in vitro assays 
still presents difficulties in terms of studying combinatorial PTM cross talk using higher-
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ordered substrates. Epigenetic in vitro assays that contain both higher-ordered 
enzymes, such as protein complexes, and substrates, such as the nucleosome core 
particle, will provide a more accurate understanding of the processes occurring in vivo 
at the level of chromatin. Finally, sensitive and quantitative means of measuring the 
gain or loss of histone modifications has been achieved utilizing site-specific antibodies 
and quantitative proteomics, yet this becomes complicated as many chromatin writer 
and eraser enzymes target multiple sites on a single histone molecule (113, 133, 165). 
Therefore, continued improvement of in vitro assays and tools for PTM detection are 
necessary for further characterization of chromatin interacting enzymes and readers.  
 Studying how the activity and interactions of effector protein complexes are 
affected in the presence of a certain PTM requires specialized substrates that are 
specifically modified at a desired residue. Here we describe a method that employs 
native chemical ligation to generate recombinant histone H3 that contains customized 
PTMs patterns. This strategy utilizes solid phase peptide synthesis and recombinant 
histone expression to generate synthetic substrates that can be modified at any given 
residue of interest without containing heterogeneous modifications on adjacent 
residues. These substrates can be further reconstituted into higher ordered nucleosome 
core particles to be tested in biologically relevant assays.    
4.2 Methods 
4.2A Peptide synthesis 
Peptides for native chemical ligation chemistry were synthesized using standard 
Fmoc-solid phase peptide chemistry on a Prelude Peptide Synthesizer (Protein 
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Technologies). However, N-terminal alanine (position 1) was Boc-Ala. Dawson TGR 
Resin (NovaBioChem) for native chemical ligation was used on a 0.1 mmole scale with 
6 equivalents of amino acids (3mLs each 2mM amino acid) for a 0.6 mmole amino acid 
coupling. A 1:1 ratio of [HATU]:[amino acid] was used. Purified peptide was lyophilized 
and its mass was confirmed with an Applied Biosystems Voyager DE-STR MALDI-TOF 
mass spectrometer (Life Technologies). Peptide sequences are as follows: 
S. cerevisiae histone H3 1-31 
Boc-ARTKQTARKSTGGKAPRKQLASKAARKSAPS-resin 
S. cerevisiae histone H3K4me3 1-31 
Boc-ARTK(me3)QTARKSTGGKAPRKQLASKAARKSAPS-resin 
4.2B Generation of Nbz C-terminal group 
Resin was washed thoroughly with DCM 3 times for 5 mins. 0.5 mmole of p-
nitrochloroformate (Sigma) in 10 mLs DCM was added to resin which rotated at room 
temp for 60 mins. Resin was thoroughly washed with DCM. 0.5M DIPEA (Sigma) in 10 
mLs of DMF (turns bright yellow upon addition) and rotated at room temp for 30 mins. 
Resin was washed thoroughly with DMF followed by a thorough washing with DCM. 
Resin was cleaved with TFA:H2O:TIS (95:2.5:2.5) for three hours. Peptide was 
precipitated with diethyl ether, dried and stored at -80 degrees C for ligation reaction. 
4.2C Cloning of truncated histone H3 for native chemical ligation 
A pET3a plasmid containing S. cerevisiae histone H3 was obtained from Dr. 
Gregory Bowman, The Johns Hopkins University. Plasmid was transformed in DH5a 
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cells and minipreps were performed to concentrate plasmid. Nested PCR was used due 
to the extensive addition of restriction sites, a Factor Xa protease site and an N-terminal 
cysteine at position 32 of histone H3. Primers are as follows: 
Forward Primer 1 
5’ GAAGGTCGTTGTGGTGGTGTTAAGAAG 3’ 
Forward Primer 2 
5’ CGCGGATCCATCGAAGGTCGTTGTGGT 3’ 
Reverse Primer 
5’ GGAGCTCGAGCTATGATCTTTCACCTCTTAA 3’ 
The first round of PCR was performed with Forward Primer 1 and Reverse 
Primer. The final product was run, excised, and purified from agarose gel. This was 
used as template for PCR round two with Forward Primer 2 and the Reverse primer 
using the product from Round one as the template. Final product insert was gel purified 
and digested with BamHI and XhoI. In addition a pET28 vector obtained from the lab of 
Dr. Gregory Bowman and digested with BamHI and XhoI and gel purified. Ligation of 
PCR product insert and pET28 was confirmed by sequencing. 
4.2D Expression and purification of truncated histone H3 for native 
chemical ligation from inclusion bodies 
Native chemical ligation truncated histone H3 construct was transformed into 
BL21 cells and plated for fresh colonies on a Kanamycin plates. An over night culture 
was grown and added to LB media and at 37°C grown until OD=0.7. Bacteria were 
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induced with 200uM IPTG and grown over night at 20°C. Bacteria were spun down at 
4°C at 8000 rpm for 10 minutes. Inclusion pellet was resuspended in Wash Buffer 
(50mM Tris-Cl pH = 7.8; 100 mM NaCl; 1 mM EDTA). Bacteria were subject to freeze 
thaw cycle and 5mM Beta-mercaptoethanol and 0.2mM PMSF were added. Cells were 
sonicated at 50% power and 50% duty cycle for 30 seconds and centrifuged at 4°C for 
20 mins at 23,000xg. Pellet was resuspended and spun down in Triton Wash Buffer 
(Wash Buffer + 1% Triton) 3 times. The inclusion pellet can be frozen at -20°C. 
Inclusion pellet is smeared alongside 50 mL conical and 1.5 mL DMSO is added 
and agitated with pellet for 30 mins. 40 mL of Extraction Buffer (7M guanidine-HCl; 20 
mM Tris pH=7.8; 10 mM B-Merc) is added to the pellet and DMSO ad let to agitate at 
room temp for 3 hours. Suspension was spun down at 23,000xg for 20 mins and Nickel 
agarose beads were added to supernatant and let agitate over night at 4°C. Beads and 
protein were washed with Extraction Buffer over a gravity column and eluted with 200 
mM imidiazole in Extraction Buffer. Elutions were dialyzed in H2O and 10 mM B-merc 
so that protein crashed out. Protein was spun down and aliquotted. 2 mg lots were 
purified over HPLC using a C8 column, and pure fractions were lyophilized. 
4.2E Factor Xa cleavage and purification of truncated histone H3 
product for native chemical ligation  
Lyophilized aliquots were resuspended in Factor Xa Buffer (1mM CaCl2; 50 mM 
NaCl; 20 mM Tris; 5 mM B-merc) and 0.5 ug Factor Xa was added and allowed to react 
at room temperature for 30 mins. Reactions were quenched by adding 8M urea. 
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Reaction products were separated over HPLC and run on SDS PAGE to determine 
fractions containing the desired singly cleaved product. 
4.2F Native chemical ligation 
Purified histone H3 tail peptide with Nbz and truncated histone H3 with N-
terminal cysteine at postion 32 were combined using an excess of peptide to protein. 
Both peptide and protein were dissolved in Ligation Buffer (0.2 M phosphate buffer 
pH=7; 0.1M 4-mercaptophenyl acetic acid (Sigma); 6M guanidine; 0.02 TCEP) and 
combined. Reaction was pH’d to 7.0 using NaOH and allowed to react overnight for 18 
hours at room temp. Reaction products were separated over HPLC and fractions were 
run over SDS PAGE to determine ligated product. 
4.2G Octamer reconstitution 
Histone H3 generated from native chemical ligation and recombinant S. 
cerevisiae histone H4, H2A, and H2B were reconstituted into histone octamers as 
described previously (150, 152). Recombinant histones H4, H2A, and H2B were 
provided by the lab of Dr. Gregory Bowman (The Johns Hopkins University, Baltimore, 
MD). 
4.3 Results 
4.3A Peptide synthesis for native chemical ligation 
The histone code hypothesis suggests that histone PTMs and certain 
combinations of PTMs recruit effector proteins and protein complexes that can elicit 
downstream biological events such as replication, transcription and DNA repair(27, 28). 
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  Developing in vitro assays that test how catalytic activity of chromatin effector enzymes 
is affected in the presence of certain PTMs would help to elucidate molecular 
mechanisms that may contribute to the histone code hypothesis. However, studying 
epigenetic processes in vitro such as PTM cross talk, how the presence of one 
modification affects the presence or absence of subsequent modification, requires 
intricate histone substrates that are modified at a single site and unmodified at a 
secondary site of interest. Moreover, ensuring that histone substrates are properly 
reconstituted into the biologically relevant nucleosome core particle is critical when 
studying substrate specificity of histone modifying enzymes. 
To generate specifically modified histone substrates we sought to use native 
chemical ligation to link a synthesized histone H3 tail peptide to a truncated histone core 
protein and further reconstitute these modified histones into nucleosomes (Figure 34). 
This technique has been previously employed to generate designer, wild-type Xenopus 
laevis histone H3 utilizing a truncated histone H3 protein with a reactive N-terminal 
cysteine. We adapted this technique to generate unmodified and H3K4me3 yeast 
histone H3 utilizing a TGR resin that results in a C-terminal Nbz chemical group on the 
histone H3 tail peptide (166). This Nbz-group is susceptible to transthioesterification via 
the reactive cysteine on the truncated histone H3 and will result in a scarless histone H3 
final product with single cysteine mutation. We can then further fold modified histone H3 
into nucleosomes to use as biologically relevant substrates in in vitro reactions. 
  We chose the ligation site to occur between residue 31 and 32 of S. cerevisiae 
histone H3 as previously reported (166). This site was chosen because mutatation of 
threonine 32 of histone H3 to a cysteine was compatible with ligation chemistry and 
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  threonine 32 is not highly conserved among species. Additionally, synthesizing a 31-
mer histone H3 tail peptide can be done with acceptable efficiency. Therefore, we 
generated both an unmodified and H3K4me3 H3 tail peptide residues 1-31 of the S. cer 
sequence using a TGR resin. Peptides were synthesized via Fmoc slid phase synthesis, 
purified over HPLC, and peptide synthesis was confirmed utilizing MALDI-TOF (Figures 
35A, 35B). Formation of the Nbz group was performed on the resin and the peptide and 
C-terminal Nbz group were cleaved and purified over HPLC and subjected to MALDI-
TOF analysis to ensure purity and the correct size of the Nbz C-terminal histone H3 tail 
peptide (Figure 35C). 
4.3B Generation of a truncated histone H3 for native chemical ligation 
A construct for a truncated histone H3 was cloned to contain S. cerevisiae 
histone H3 residues 33-136 and a cysteine in position 32 in place of the native 
threonine (Figure 36A). Additionally an N-terminal 6X-his tag was added for purification 
and a Factor Xa protease cleavage site was used to remove the tag and leave a free N-
terminal cysteine necessary to carry out the native chemical ligation reaction. This 
construct was transformed into E. coli and induced using IPTG and expression was 
confirmed using a western blot against the C-terminus of histone H3 (Figures 36B, 
36C).  The protein was further purified from insoluble inclusion bodies and bound, 
washed, and eluted from Nickel agarose beads to obtain a pure product (Figures 37A, 
37B). After purification, the N-terminal tag was cleaved using Factor Xa protease to 
leave an N-terminal cysteine residues necessary for the reaction with the Nbz peptide. 
The Factor Xa protease also promiscuously cleaves at an off-target site on the C-
terminal region of histone H3 (Figure 38A) (166). Therefore uncleaved, singly cleaved, 
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  and doubly cleaved histone H3 products were separated over HPLC and the fractions 
were confirmed over an SDS PAGE gel, so that the desired singly cleaved product 
could be isolated (Figures 38B). 
4.3C Histone H3 native chemical ligation and histone octamer 
reconstitution 
The histone H3 tail peptide residues 1-31 and the truncated histone H3 protein 
residues 33-136 with a cysteine residue at position 32 were subjected to a small-scale 
native chemical ligation reaction (Figure 39A). We observed a shift in size from a 12 
kDa truncated protein to a 15 kDa ligated histone H3 product indicating the reaction had 
proceeded to a fully ligated histone H3 protein. We performed the native chemical 
ligation of histone H3 on a larger scale where the reaction was separated over HPLC 
and after fractions were run on an SDS-PAGE gel, we concluded that the first HPLC 
peak contained our ligated histone H3 product (Figures 39B, 39C). Finally, using 
recombinantly expressed histone H4, H2A, and H2B obtained from the lab of Dr. 
Gregory Bowman (The Johns Hopkins University, Baltimore, MD), we reconstituted 
recombinant S. cerevisiae histone octamers (Figures 40A, 40B). 
 
4.4 Discussion 
Designing in vitro assays that provide a biologically relevant depiction of what is 
occurring in vivo is critical when understanding the fundamental processes of epigenetic 
mechanisms. Overcoming challenges associated with in vitro assays such as working 
with enzymatic subcomplexes or complexes, using nucleosomal templates as 
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 substrates, measuring enzymatic activity on substrates with multiple target sites, and 
studying PTM cross-talk would provide a more accurate representation of chromatin 
regulation. Using native chemical ligation we generated specifically modified histone 
substrates, which were further reconstituted into histone octamers. Because these 
histones were generated using solid phase peptide synthesis and recombinant protein 
expression we can obtain a homogenously modified histone H3 substrate (166). This 
provides an advantage over histone substrates generated from enzymatic reactions or 
purified from lysates as they can contain numerous modifications. 
Because the Gcn5 subcomplex also interacts with the tandem Tudor domain 
containing protein Sgf29, reported to bind H3K4me3, we aimed to generate a ligated 
histone H3 that contains the H3K4me3 modification (88, 167). Furthermore, this 
technique can be used to study at acetyl-lysine and bromodomain mediated HAT 
activity of Gcn5 by generating histones that are differentially pre-acetylated at various 
lysine residues and measuring how Gcn5 HAT activity is altered upon these specific 
acetyl marks. How these modifications and others that have been predicted to be 
involved with histone H3 acetylation cross talk, such as histone H3 serine 10 
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Appendix 
A.1 Recombinant expression of Gcn5 HAT module subunits 
When studying in vitro enzymatic activity of histone writer and eraser enzymes, it 
is critical to ensure biologically relevant enzymes and substrates are being utilized. This 
can prove difficult when studying histone-modifying enzymes as they are often found in 
large, multisubunit protein complexes, such as SAGA, CoREST, and Polycomb 
Repressive Complex or exist as very large proteins with multiple domains, such as 
P300 (85, 92, 169, 170). When studying enzymatic activity of chromatin proteins, taking 
the associated reader motifs and DNA binding domains into account is extremely critical 
as these could impact substrate specificity and kinetic parameters. For example, 
monomeric Gcn5 is unable to acetylate nucleosomes, its biological substrate, in vitro 
(78, 96, 116). However, when Gcn5 is in the context of its binding partners, Ada2 and 
Ada3, which contain nucleosome and DNA binding domains, the nucleosome core 
particle is extensively acetylated by Gcn5 (79, 96, 116).  
Recombinant subcomplexes and complexes can be expressed in tandem using a 
polycistronic vector containing genes of the desired complex or subcomplex that can be 
expressed in E. coli. A polycistronic vector containing the genes for S. cerevisae Gcn5, 
Ada2, and an N-terminal truncated Ada3 has been developed by the laboratory of Dr. 
Song Tan, in which they have optimized a protocol to express and purify the intact 
trimeric subcomplex (117). Because this trimeric subcomplex interacts with additional 
proteins in complexes such as SAGA and ADA, we speculated that the N-terminal 
region may be necessary for interactions with other subunits, so we generated a new 
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polycistronic clone that contained the full length Ada3 protein (Figure 41A). 
Furthermore, additional complex members can be recombinantly expressed individually. 
The protein Sgf29, which contains a tandem Tudor domain capable of binding 
H3K4me3, has also been shown to interact with the Gcn5 trimeric subcomplex as it is 
found to recruit SAGA to promoters via its interaction with H3K4me3 (88, 160). S. 
cerevisiae Sgf29 was expressed with a cleavable MBP tag to improve solubility, and we 
were able to obtained pure, recombinantly expressed Sgf29 (Figure 41B).  
A.2 H3K4 trimethylation affects activity of the Gcn5 HAT module  
Association of recombinantly expressed S. cerevisiae Sgf29 with the S. 
cerevisiae Gcn5 subcomplex proved to be difficult as Sgf29 would not interact with the 
subcomplex. However, when S. pombe Sgf29 and the Gcn5 subcomplex were 
recombinantly expressed, this resulted in a stable Gcn5/Ada2/Ada3/Sgf29 subcomplex 
termed the Gcn5 module. Because Sgf29 contains the H3K4me3-binding tandem tudor 
domain, the activity of the Gcn5 HAT module was compared on unmodified 
nucleosomal histone H3 and H3K4me3 nucleosomal histone H3 substrates. Overall 
histone H3 acetylation patterns and site specific acetylation was observed using acid- 
urea gel resolution and western blot analysis with general histone H3 and site specific 
antibodies (Figure 42).  
We observed that when the H3K4me3 mark was present, the rate and overall 
acetylation on histone H3 was enhanced by Gcn5 HAT module when observing western 
blots for total histone H3. Site specific antibodies revealed that H3K14ac occurred on 
the first acetylation state (band 1) in both the unmodified and H3K4me3 substrates, 
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  which was in agreement with our earlier findings and previous work (Figure 42)  (111, 
113). The site specificity of HAT module acetylation did not appear to be significantly 
altered between unmodified and H3K4me3 substrates since acetylation of specific 
residues (K14, K23, K18) occurred on the same acetylation state bands between both 
substrates. However, the rates among the specific acetylation events of H3K18 and 
H3K14 were observed to be more significantly altered than that of H3K23, which 
becomes evident at later times points (2.5 mins) by comparing the acetylation patterns 
between unmodified and H3K4me3 substrates (Figure 42). These results are in 
agreement with a previous study that reports a decrease in H3K14ac and H3K18ac 
levels in vivo when Sgf29 was deleted (160). This work was performed in collaboration 
with Alison E. Ringel and the lab of Dr. Cynthia Wolberger.  
A.3 TAP-tag purification of yeast HAT complexes and HAT assays 
While recombinant expression of certain protein complexes can increase purity 
and yield, problems with solubility may arise especially because some effector 
complexes, such as SAGA, contain over 15 protein subunits (88). Additionally, proteins 
within these complexes may be modified by PTMs in vivo that could affect enzymatic 
activity, stability, protein architecture, and substrate specificity, which would otherwise 
be lost when complexes are recombinantly expressed in E. coli. Therefore, by purifying 
endogenous complexes from eukaryotic organisms, such as yeast, we can obtain 
effector complexes in their entirety and with endogenous modifications. We used 
recombinant expression from a polycistronic vector and TAP-tag pulldowns of 
endogenous HAT complexes to test in vitro activity of these enzymes in the context of 
their binding partners 
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  We have successfully purified the ADA complex, consisting of the proteins Gcn5, 
Ada2, Ada3, Sgf29, Ahc1, and Ahc2 performed in the lab of Dr. Alan J. Tackett 
(University of Arkansas for Medical Sciences, Little Rock, AR). Unlike Gcn5, Ada2, 
Ada3 and Sgf29, all of which are found in additional complexes, Ahc1 and Ahc2 are 
distinct to the ADA complex (88). Therefore, to ensure we were not pulling down 
multiple complexes, we tagged Ahc1 with a TAP-tag in which we purified the six-
membered ADA complex from S. cerevisiae (Figure 43A). We observed a very strong 
interaction among these proteins as all complex members remained intact after washing 
with up to 500mM salt. This endogenous ADA complex was shown to be active in an in 
vitro HAT assays where it acetylates histone H3 (Figure 43B). In addition to the 
endogenously purified ADA complex, two subsets of the NuA3 complex, NuA3a and 
NuA3b, were purified by Dr. Tonya M. Gilbert and HAT assays were performed with 
recombinant histone H3 and resolved over an acid-urea gel (Figure 44) (34). Acid-urea 
gel analysis revealed that the ADA complex acetylated up to 6 sites on histone H3.  
A.4 Cryo EM of the six-member ADA complex 
While TAP-tag purification provides full-membered, endogenously modified 
complexes it cannot yield protein amounts sufficient for crystallography. However, 
advances in Cryo-EM, which require a much lesser amount of protein, may lend 
structural insight into these large multisubunit protein complexes. We obtained 
preliminary Cryo-EM structural data on the intact endogenous ADA complex, which 
revealed three unique averages of the complex structure (Figures 45A, 45B) (in 
collaboration with Johnathan Chittuluru and Dr. Francisco Asturias (Scripps, San Diego, 
CA). 
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  A.5 Quantitative mass spectrometry for measuring histone H3K4 
methylation  
In addition to measuring in vitro acetylation on lysine residues, quantitative mass 
spectrometry was also used to measure the effectiveness of an inhibitor against the 
lysine demethylase, LSD1. LSD1 is an actively pursued drug target as it is involved in 
many disease states and is known to demethylate H3K4me2 (63, 171). This method, 
termed MassSQUIRM (mass spectrometric quantitation using isotopic reductive 
methylation), which exploits the reactive methylation of amine groups using deutero-
formaldehyde to chemically methylate all lysine residues resulting in a dimethylated 
state (172, 173). We developed an assay to test the effectiveness of a new LSD1 
inhibitor (12d or bizine). Using massSQUIRM we were able to show that this inhibitor 
prevented LSD1 from demethylating H3K4me2 to an unmodified H3K4 state (63) 
(Figure 46). 
A.6 Methods 
NuPAGE SDS PAGE 12% gels (Invitrogen) were used to resolve histone H3. 
Acid-urea gels were assembled and run as previously described  (120). Gels were 
washed with nano-pure water and stained with SimplyBlue Safe Stain (Invitrogen). 
 
The following methods were done in collaboration with Alison E. Ringel, Lab of 
Dr. Cynthia Wolberger, and used for HAT module reactions on unmodified and 
H3K4me3 nucleosomal substrates. Nucleosomes were acetylated in buffer containing 
20 mM HEPES, pH 7.6, 50 mM NaCl, 1 mM DTT, 50 µM acetyl-CoA, 20 
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  µg/mL BSA and 0.2 µM or 1 µM Xenopus nucleosome core particle (NCP). Reactions 
were incubated in buffer at 30°C for five minutes, initiated by the addition of 50 nM HAT 
module, quenched at different time points by flash-freezing in liquid nitrogen, and then 
lyophilized for analysis by acid-urea gel electrophoresis. Acid-urea gels were assembled 
and run as previously described (120). Histones were visualized with either SYPRO 
Ruby protein stain (LifeTechnologies) or by western blotting. For western blotting, 
proteins were transferred to PVDF membrane as previously described  (120). 
Membranes were blocked overnight in 5% nonfat milk at 4°C and washed in TBS. 
Primary antibodies were diluted in 1% nonfat milk in TBS supplemented with 0.1% 
Tween (TBST) as follows: anti-H3 (Abcam ab1791, 1/25,000), anti-H3K14ac (07-353, 
EMD Millipore, 1/5000), anti-H3K18ac (EMD Millipore 07-354, 1/7500), anti-H3K23ac 
(EMD Millipore 07-355, 1/5000), or anti-H3K4me3 (Abcam ab8580, 1/5000). Each 
primary antibody was applied for 1 hour at room temperature followed by washing in 
TBST. Goat anti-rabbit IgG-horseradish peroxidase secondary antibody (Amersham 
Biosciences) was diluted to 1/5000 in 1% nonfat milk and TBST and applied for 1 hour 
at room temperature and washed in TBST. Blots were developed using Pierce ECL 
Western Blotting Substrate (ThermoScientific) and exposed using film. 
 
Purifications of endogenously TAP-tagged S. cerevisiae NuA3a (YNG1;pdp3∆), 
NuA3b (PDP3), and ADA (Ahc1) were performed to maintain complex integrity as 
previously described  (34). Complexes were resuspended in HAT buffer (20 mM Tris pH 
7.5, 50 mM NaCl, 5% glycerol) and mixed with 1 µg of recombinantly expressed S. 
cerevisiae histone H3 and 30 µM acetyl CoA in a total volume of 60 µL. Acetyl CoA was 
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  omitted from the negative control reactions. All reactions were incubated for 30 min at 
30 °C and frozen in liquid nitrogen. TAP-tag purifications were performed by Dr. Tonya 
M. Gilbert. 
 
MassSQUIRM inhibition experiments were performed in triplicate as described 
previously12. The reaction mixtures containing 13.3 µM H3K4me2-biotin peptide (1 
ARTKme2QTA RKS TGG KAP RKQ LYKbio), 50 mM HEPES (pH 7.5), and 50 µM 
phenelzine or 12d, were incubated at 25 °C for 5 min, prior to initiation with 215 nM 
GST-LSD1. The demethylase reactions were run at 25 °C for 30 min and then analyzed 
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through gap junctions during a university-wide conference. 
 
 
• Centocor Scholarship              Academic Year 2008 
West Chester University of Pennsylvania 
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• Co-President                      June 2014 – present  
Hopkins Biotech Network (HBN) 
HBN connects the Johns Hopkins community with the biotechnology and 
pharmaceutical industries, with a network of over 2000 representatives from the 
science and business sectors. Developed and implemented a plan to increase 
the HBN budget and expand HBN membership. Together, these strategies 
resulted in the recruitment of faculty sponsors and board members and increased 
funds that were used to: 
o Design and launch a new website 
o Generate a new organization logo 
o Organize and implement a bio-entrepreneurial training initiative 
o Assemble a committee for corporate outreach 
o Extend the HBN brand across Johns Hopkins campuses to unite 
scientists, business students, and biotechnology professionals 
 
• Director of Industry Relations     August 2013 – June 2014 
Hopkins Biotech Network (HBN) 
Responsible for collaboratively working with a team and utilizing effective 
communication to establish partnerships with local biotech and pharmaceutical 
companies. Successfully implemented funding guidelines and expectations of 
corporate sponsors. Organized and hosted 3 career events that were attended 
by hundreds of Johns Hopkins students.  
 
 
• Grants Team Member      June 2013 – August 2014 
Charm City Clinic 
Volunteered for non-profit health clinic in East Baltimore run by medical, graduate 
and undergraduate students. Responsibilities included identifying funding 
opportunities, hosting and organizing fundraisers, determining clinic eligibility, 
and filling out grant applications. 
 
 
• Incentive Mentoring Program                    April 2011 – June 2014 
Dunbar High School, Baltimore, MD 
Served as a mentor for underrepresented high school students. Collaborated 
with a group of volunteers to coach, tutor, and guide students in planning for 
future educational and career options. Over 90% of students graduate high 
school and were accepted in a 2 or 4 year university. 
 
 
• Healthcare Case Manager      June 2013 – August 2014 
Charm City Clinic 
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Worked with a nonprofit health clinic in the City of Baltimore and consulted with 
clients to provide them with a better understanding of healthcare options and 
ensuring they are receiving proper benefits.  
 
 
• Center for Talented Youth Mentor           Summer 2012 and Summer 2013 
The Johns Hopkins University  
Supervised and trained two junior scientists in learning laboratory techniques, 
organizing a summer research project, and preparing a poster presentation. 
These individuals are now undergraduate researchers performing cutting-edge 
research at premier US universities.  
 
 
 
 
 
 
 
 
